


FORM PTO-139G (Rev. 10-96)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 001560-349	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.51) 09/147947 Unassigned	
INTERNATIONAL APPLICATION NO. PCT/JP 98/03324		INTERNATIONAL FILING DATE 24 July 1998		PRIORITY DATE CLAIMED 24 July 1997	
TITLE OF INVENTION NOVEL SERINE PROTEASE					
APPLICANT(S) FOR DO/EO/US Nobuo TSURUOKA, Kyoko YAMASHIRO and Nozomi YAMAGUCHI					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.					
2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.					
3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and the PCT Articles 22 and 39(1).					
4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.					
5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))					
a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).					
b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.					
c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)					
6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).					
7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))					
a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).					
b. <input type="checkbox"/> have been transmitted by the International Bureau.					
c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.					
d. <input checked="" type="checkbox"/> have not been made and will not be made.					
8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).					
9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).					
10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).					
Items 11. to 16. below concern other document(s) or information included:					
11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.					
12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.					
13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.					
<input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.					
14. <input type="checkbox"/> A substitute specification.					
15. <input type="checkbox"/> A change of power of attorney and/or address letter.					
16. <input checked="" type="checkbox"/> Other items or information:					
* Notice Informing the Applicant of the Communication of the International Application to the Designated Offices and					
* International Search Report					

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.50) Unassigned		INTERNATIONAL APPLICATION NO. PCT/JP 98/03324		ATTORNEY'S DOCKET NUMBER 001560-349	
17. <input type="checkbox"/> The following fees are submitted:				CALCULATIONS	PTO USE ONLY
Basic National Fee (37 CFR 1.492(a)(1)-(5)): Search Report has been prepared by the EPO or JPO \$840.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) \$670.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$760.00 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$970.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$96.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =					
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$	
Claims	Number Filed	Number Extra	Rate		
Total Claims	20 -20 =	0	X\$18.00	\$	0.00
Independent Claims	4 -3 =	1	X\$78.00	\$	78.00
Multiple dependent claim(s) (if applicable)			+ \$260.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$	918.00
Reduction for 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$	0.00
SUBTOTAL =				\$	918.00
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$	0.00
TOTAL NATIONAL FEE =				\$	0.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	40.00
TOTAL FEES ENCLOSED =				\$	958.00
				Amount to be:	
				refunded	\$
				charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>958.00</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. <u>02-4800</u> in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>02-4800</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> Ronald L. Grudziecki, Esq. BURNS, DOANE, SWECKER & MATHIS, L.L.P. P.O. Box 1404 Alexandria, Virginia 22313-1404 </div> <div style="width: 45%; text-align: center;">  SIGNATURE Donna M. Meuth NAME <u>36,607</u> REGISTRATION NUMBER </div> </div>					

09/147947
510 Rec'd PCT/PTO 24 MAR 1999

Patent
Attorney's Docket No. 001560-349

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
)
Nobuo TSURUOKA et al) Group Art Unit: Unassigned
)
Application No.: Unassigned) Examiner: Unassigned
Corresponding to PCT/JP 98/03324)
)
Filed: March 24, 1999)
)
For: NOVEL SERINE PROTEASE)

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination on the merits, please amend the above identified application as follows:

IN THE SPECIFICATION:

In compliance with 37 C.F.R. § 1.823(a), please insert the attached copy of the "Sequence Listing" after page 28 and before the claims of the above-identified application.

IN THE CLAIMS:

Please amend claims 5, 6, 7, 10, and 11 as follows:

In claim 5, lines 2 and 3, please delete "in any one of the above-mentioned claims 1 to 4" and insert therefore --claim 1--.

In claim 6, lines 4 and 5, please delete "in any one of the above-mentioned claims 1 to 4" and insert therefore --claim 1--.

7. (Amended) An expression vector containing the DNA as claimed in [claims 5 or 6] claim 5.

In claim 10, lines 2 and 3, please delete "in any one of claims 1 to 4" and insert therefore --claim 1--.

11. (Amended) A process for screening physiologically active substance that uses the serine protease, domain or their partial peptides as claimed in claim 1 [any one of claims 1 to 4, or the DNA as claimed in claim 5 or 6].

Please add the following new claims:

--12. An expression vector containing the DNA as claimed in claim 6.

13. A process for screening physiologically active substance that uses the DNA as claimed in claim 5.

14. DNA which codes for the serine protease, domain or their partial peptides as claimed in claim 2.

15. DNA which codes for the serine protease, domain or their partial peptide as claimed in claim 3.

16. DNA which codes for the serine protease, domain or their partial peptide as claimed in claim 4.

17. An antibody whose antigen is the serine protease, domain or their partial peptide as claimed in claim 2.

18. An antibody whose antigen is the serine protease, domain or their partial peptide as claimed in claim 3.

19. An antibody whose antigen is the serine protease, domain or their partial peptide as claimed in claim 4.

20. A process for screening physiologically active substances that uses the DNA as claimed in claim 6.--

REMARKS

Entry of the foregoing and examination of the above-identified application is respectfully requested.

The paper copy of the Sequence Listing for the subject application, is by this amendment, added after page 28 and before the claims of the above-identified application. Please renumber the pages accordingly.


Claims 5, 6, 7, 10, and 11 have been amended to eliminate the multiple dependency of the claims. New claims 12-20 have been added, directed to preferred embodiments of the invention. These claims are supported by the original claims 1-11. No new matter has been added by these amendments.

Early and favorable action in the form of a Notice of Allowance is respectfully requested.

In the event that there are any questions relating to this amendment or the application in general, it would be appreciated if the Examiner would contact the undersigned attorney by telephone so that prosecution would be expedited.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 
Donna M. Meuth
Registration No. 36,607

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: March 24, 1999

SPECIFICATION

NOVEL SERINE PROTEASE

5 Technical Field

The present invention relates to a novel serine protease, DNA coding therefor, a process for production of said serine protease, and a process for screening physiologically active substances using said serine protease or DNA coding therefor.

10

Background Art

Serine proteases are widely present in animals, plants and microorganisms, and are known to be involved in an extremely large number of biological reactions including food digestion, blood coagulation and fibrinolysis, complement activation, hormone production, ovulation and fertilization, phagocytosis, cell growth, development and differentiation, aging and cancer metastasis, particularly in higher animals (Neurath, H., Science, 224, 350-357, 1984).

15 20

In recent years, serine proteases have been confirmed to act as a physiologically important functional molecule in the central nervous system as well. For example, known serine proteases occurring in the brain include tissue plasminogen activator (Sappiro, A-D., Madani, R., Huarte, J., Belin, D., Kiss, J.Z., Wohlwent, A. and Vassalli, J-D., J. Clin. Invest., 92, 679-685, 1993), thrombin (Monard, D., Trends Neurosci., 11, 541-544, 1988), human trypsin IV (Wiegand, U., Corbach, S., Minn, A., Kang, J. and Müller-Hill, B., Gene, 136, 167-175, 1993), neuropsin (Chen, Z-L., Yoshida, S., Kato, K., Momota, Y., Suzuki, J., Tanaka, T., Ito, J., Nishino, H., Aimoto, S., Kiyama, H. and Shiosaka, S., J. Neurosci., 15(7), 5088-5097, 1995), and neurosin (Yamashiro, K., Tsuruoka, N., Kodama, S., Tsujimoto, M., Yamamura, Y., Tanaka, T., Nakazato, H. and

25 30 35

Yamaguchi, N., *Biochim. Biophys. Acta*, 1350, 11-14, 1997).

Not only are these serine proteases in the brain involved in the deployment of the neurite outgrowth of neurons, but they are also assumed to be involved in the synapse-formation process with target neurons (Liu, Y., Fields, R.D., Fitzgerald, S., Festoff, B.W. and Nelson, P.G., *J. Neurobiol.*, 25, 325, 1994).

However, the physiological functions of these serine proteases in the brain are essentially unknown. In addition, although it is predicted that many other serine proteases exist that occur in the brain and are responsible for performing important physiological functions, the majority of these are still not identified.

On the other hand, certain types of serine protease proteins in the coagulation, fibrinolysis and complement system have the kringle domains, EGF-like structures, finger structures, γ -carboxyglutamic acid domains, apple domains and other structures on their N-terminus (Furie, B. and Furie, B.C., *Cell*, 53, 505-518, 1988). Examples of known serine protease proteins having some kringle domains include urokinase, plasminogen activator and plasminogen.

The kringle domains have the ability to bind with fibrin, heparin and lysine analogue (Scanu, A.M. and Edelstein, C., *Biochimica. Biophysica. Acta*, 1256, 1-12, 1995), and in the blood fibrinolysis system, plasminogen activator has been known to bind the precipitated fibrin by means of its kringle domains, following activation of nearby bound plasmin. Moreover, the angiogenesis inhibitory factor, angiostatin, has been identified to be the kringle domains in a plasminogen molecule (Cao, Y., Ji, R.W., Davidson, D., Scaller, J., Martí, D., Söndel, S., McCance, S.G., O'Reilly, M.S., Llinás, M. and Folkman, J., *J. Biol. Chem.*, 271, 29461-29467, 1996), and was shown for the first time to have physiological

activity as an independent Kringle domain, that provided the first demonstration of the physiological activity as kringle domains alone.

5 In addition, the existence of a series of protein groups including cyclophilin-C binding protein, speract receptor, complement factor I, CD5 and CD6 is known that have the scavenger receptor cysteine-rich (SRCR) domains observed in the macrophage scavenger receptor (Resnick, D., Pearson, A. and Krieger, M., Trends. Biochem. Sci., 10 19, 5-8, 1994).

In contrast to cyclophilin-C binding protein and complement factor I being secretory proteins, speract receptor, CD5 and CD6 are known to be membrane-bound proteins. Among these, a protein binding to membrane-bound protein CD6 was found to be the activated leukocyte adhesive molecule (ALCAM), and its binding site was localized to a SRCR domain structure of CD6 (Whitney, G.S., Starling, G.C., Bowen, M.A., Modrell, B., Siadak, A.W. and Aruffo, A.J., J. Biol. Chem., 270, 18187-18190, 20 1995).

Moreover, ALCAM, which is a ligand of CD6, is known to be expressed by activated lymphocytes and neurons, while CD6 is surmised to fulfill a certain regulatory function for maintaining homeostasis in the immune system and nervous system by means of the interaction with ALCAM. 25

In this manner, proteins composed of multi-domain structures not only have characteristic functions associated with each domain, but also are considered to function by having specific recognition functions interacting with each domain function. 30

Disclosure of the Invention

In consideration of the present circumstances as described above, the object of the present invention is 35 to provide a novel serine protease, and a novel serine protease DNA that codes for it. Moreover, another object

of the present invention is to provide a process for producing a large amount of said protease using said DNA, and a process for screening physiologically active substances using said serine protease or DNA that codes for it.

As a result of repeated earnest research, the inventors of the present invention isolated cDNA that codes for a novel functional protein by screening cDNA having a characteristic 5' translation region using a region preserved well in cDNA for the probe that codes for serine protease occurring in the brain, thereby leading to completion of the present invention.

Thus, the present invention provides (1) a serine protease or its partial peptide containing an amino acid sequence identical to serine protease indicated in Figs. 7 to 12 (SEQ ID NO: 6), an amino acid sequence in which a portion of the identical amino acid sequence is deleted or substituted, or an amino acid sequence in which at least one amino acid is added to the identical amino acid sequence or an amino acid sequence in which a portion of the identical amino acid sequence is deleted or substituted.

Moreover, the present invention provides (2) a serine protease domain or its partial peptide containing an amino acid sequence identical to a serine protease domain comprising the amino acid sequence from amino acid no. 578 to 822 indicated in Figs. 7 to 12 (SEQ ID NO: 6), an amino acid sequence in which a portion of the identical sequence is deleted or substituted, or an amino acid sequence in which at least one amino acid is added to the identical amino acid sequence or an amino acid sequence in which a portion of the identical amino acid sequence is deleted or substituted.

Moreover, the present invention provides (3) a kringle domain or its partial peptide containing an amino acid sequence identical to a kringle domain comprising the amino acid sequence from amino acid no. 40 to 112

indicated in Figs. 7 to 12 (SEQ ID NO: 6), an amino acid sequence in which a portion of the identical sequence is deleted or substituted, or an amino acid sequence in which at least one amino acid is added to the identical amino acid sequence or an amino acid sequence in which a portion of the identical amino acid sequence is deleted or substituted.

Moreover, the present invention provides (4) a scavenger receptor cysteine-rich (SRCR) domain or its partial peptide containing an amino acid sequence identical to an SRCR domain comprising the amino acid sequence from amino acid no. 117 to 217, from amino acid no. 227 to 327, from amino acid No. 334 to 433, or from amino acid No. 447 to 547 indicated in Figs. 7 to 12 (SEQ ID NO: 6), an amino acid sequence in which a portion of the identical sequence is deleted or substituted, or an amino acid sequence in which at least one amino acid is added to the identical amino acid sequence or an amino acid sequence in which a portion of the identical amino acid sequence is deleted or substituted.

Moreover, the present invention provides (5) DNA which codes for the serine protease, domain or their partial peptides as set forth in any one of the above-mentioned (1) to (4).

Moreover, the present invention provides (6) DNA which codes for a peptide having serine protease, domain or their partial peptide activity, and is hybridizable with DNA that codes for the serine protease, domain or their partial peptides as set forth in any one of the above-mentioned (1) to (4) under stringent conditions.

Moreover, the present invention provides (7) an expression vector containing the DNA as set forth in the above-mentioned (5) or (6).

Moreover, the present invention provides (8) a host transformed by the expression vector as set forth in the above-mentioned (7).

Moreover, the present invention provides (9) a

process for preparing of serine protease, domain or their
partial peptides comprising culturing or breeding the
host as set forth in the above-mentioned (8), and
harvesting serine protease, domain or their partial
peptides.

Moreover, the present invention provides (10) an
antibody whose antigen is the serine protease, domain or
their partial peptides as set forth in any one of the
above-mentioned (1) to (4).

Moreover, the present invention provides (11) a
process for screening physiologically active substances
that uses the serine protease, domain or their partial
peptides as set forth in any one of the above-mentioned
(1) to (4), or the DNA as set forth in the above-
mentioned (5) or (6).

Brief Description of the Drawings

Fig. 1 indicates a portion of the nucleotide
sequence of cDNA that codes for mouse serine protease,
and its corresponding amino acid sequence.

Fig. 2 indicates a portion of the nucleotide
sequence of cDNA that codes for mouse serine protease,
and its corresponding amino acid sequence.

Fig. 3 indicates a portion of the nucleotide
sequence of cDNA that codes for mouse serine protease,
and its corresponding amino acid sequence.

Fig. 4 indicates a portion of the nucleotide
sequence of cDNA that codes for mouse serine protease,
and its corresponding amino acid sequence.

Fig. 5 indicates a portion of the nucleotide
sequence of cDNA that codes for mouse serine protease,
and its corresponding amino acid sequence.

Fig. 6 indicates a portion of the nucleotide
sequence of cDNA that codes for mouse serine protease,
and its corresponding amino acid sequence.

Fig. 7 indicates a portion of the nucleotide
sequence of cDNA that codes for human serine protease,

and its corresponding amino acid sequence.

Fig. 8 indicates a portion of the nucleotide sequence of cDNA that codes for human serine protease, and its corresponding amino acid sequence.

5 Fig. 9 indicates a portion of the nucleotide sequence of cDNA that codes for human serine protease, and its corresponding amino acid sequence.

10 Fig. 10 indicates a portion of the nucleotide sequence of cDNA that codes for human serine protease, and its corresponding amino acid sequence.

Fig. 11 indicates a portion of the nucleotide sequence of cDNA that codes for human serine protease, and its corresponding amino acid sequence.

15 Fig. 12 indicates a portion of the nucleotide sequence of cDNA that codes for human serine protease, and its corresponding amino acid sequence.

Fig. 13 is an electrophoresis diagram indicating the results of Northern blotting that shows transcription of serine protease gene in various mouse organs.

20

Mode for Carrying Out the Invention

25 Cloning of cDNA coding for mouse serine protease was performed by first preparing a cDNA library from mouse brain mRNA isolated and prepared in accordance with conventional methods, and then performing PCR using the cDNA library and PCR primers designed and prepared based on a serine protease motif. Using the resulting PCR product as a probe, clones were screened having a long 5' translation region and expected to code for a novel functional protein.

30

35 As a result, the inventors of the present invention succeeded in isolating a 2.7 kb cDNA named mouse BSSP-3. As a result of investigating the resulting cDNA sequence in accordance with conventional methods, mouse BSSP-3 cDNA was determined to code for a novel functional protein that contains not only a serine protease domain, but also a kringle domain and scavenger receptor

cysteine-rich domains. The isolated mouse BSSP-3 cDNA coded for one Kringle domain, three scavenger receptor cysteine-rich domains, and one serine protease domain. A specific example is described in Example 1.

5 Next, when expression of mouse BSSP-3 mRNA was confirmed in various mouse organs and various sites of mouse brain using the entire length of the isolated mouse BSSP-3 cDNA as a probe, with respect to expression in various mouse organs, strong expression was observed
10 particularly in the brain, while expression was also observed in the lung and kidney. In addition, with respect to various sites of mouse brain, strong expression was observed in the cerebrum and brain stem, and expression was also observed in the medulla
15 oblongata. The size was only about 2.7 kb in all cases. Of the various sites in the brain that were examined, expression of mouse BSSP-3 mRNA was not observed in the cerebellum. A specific example is described in Example 2. Based on these findings, mouse BSSP-3 mRNA was
20 confirmed to actually be expressed in mouse organs.

Moreover, as a result of screening the human brain cDNA library using mouse BSSP-3 cDNA as a probe, human BSSP-3 cDNA was able to be successfully isolated. As a
25 result, the inventors of the present invention clearly showed that human BSSP-3 cDNA clearly differs from that which would be predicted from the primary structure of mouse BSSP-3 cDNA, and was determined to code for one kringle domain, four scavenger receptor cysteine-rich domains, and one serine protease domain. A specific
30 example is described in Example 3. Moreover, when the inventors of the present invention expressed human BSSP-3 cDNA coding for serine protease mature protein in COS-1 cells, it was clearly determined to be a functional protein having enzyme activity. A specific example is
35 described in Example 4.

Based on the above results, in terms of its primary structure, the mouse and human BSSP-3 cDNAs isolated here

encode a novel functional protein that not only contain a novel serine protease domain, a novel kringle domain and novel scavenger receptor cysteine-rich domains, but also is functional proteins in which the serine protease domain has enzyme activity.

Not only is it clear that the novel functional protein in the present invention has complex functions due to its primary structure, but it also plays a certain role in the physiological function of the brain through the complex functions. Thus, the mouse BSSP-3 cDNA and novel functional protein encoded by the mouse BSSP-3 cDNA of the present invention provide useful means for pathological analysis of various types of mouse disease models. In addition, the human BSSP-3 cDNA and novel functional protein encoded by human BSSP-3 cDNA of the present invention also provide useful means for screening therapeutic agents for various types of diseases based on useful information for disease treatment obtained through pathological analysis. Moreover, they can also be applied to the development of therapeutic drugs for actual human diseases.

Examples of these treatment methods include supplementary treatment by administration of the recombinant protein and the gene-expression promotion or inhibition therapy by the sense or antisense method. Moreover, each of the domain structures of the novel functional protein can also function independently. Thus, molecules that exhibit interaction with each domain structure can be identified after expressing each domain structure separately. In addition, by investigating the involvement in disease of the identified molecule group, supplementary treatment by administration of the recombinant protein and gene-expression promotion or inhibition therapy by the sense or antisense method can be applied.

The following provides an explanation of the present invention based on its examples.

Although the present invention discloses the nucleotide sequence indicated in Figs. 1 to 6 (SEQ ID NO: 3) and Figs. 7 to 12 (SEQ ID NO: 5) as nucleotide sequences of DNA that code for novel serine proteases, the serine protease DNAs of the present invention are not limited to them. Once the amino acid sequence of naturally-occurring serine protease is determined, various nucleotide sequences that code for the same amino acid sequence can be designed based on codon degeneration and prepared. In this case, it is preferable to use codons that are used at high frequency in a host to be used.

In order to obtain DNA that codes for naturally-occurring serine protease of the present invention, although cDNA can be obtained in the manner described in the examples, it is not limited to this. Namely, once a single nucleotide sequence that codes for the amino acid sequence of naturally-occurring serine protease is determined, DNA coding for naturally-occurring serine protease can be cloned as cDNA by a strategy that differs from the strategy specifically disclosed in the present invention. Moreover, it can also be cloned from a genome of cells that produce it.

For example, the above-mentioned DNA can be cloned by the polymerase chain reaction (PCR) method using a DNA (nucleotide) primers as shown in Example 1.

The DNA of the present invention also codes for a protein or glycoprotein having serine protease activity, and includes DNA that hybridizes with the nucleotide sequence of Figs. 1 to 6 (SEQ ID NO: 3) or Figs. 7 to 12 (SEQ ID NO: 5). In addition, typical hybridization methods are well known among persons with ordinary skill in the art (examples of which include Experimental Medicine, special edition, Yodosha Publishing, "Biotechnology Experimental Method Series - Gene Engineering General Collection", Vol. 1.5, No. 11, pp. 24-60, 1987), and measurement of activity is also well

known among persons with ordinary skill in the art.

In the case of cloning from a genome, the various primer nucleotides or probe nucleotides used in the examples can be used as probes for selecting genome DNA fragments. In addition, other probes can also be used that are designed based on the nucleotide sequence described in Figs. 1 to 6 (SEQ ID NO: 3) or Figs. 7 to 12 (SEQ ID NO: 5). Typical methods for cloning a target DNA from the genome are also well known among persons with ordinary skill in the art (Current Protocols in Molecular Biology, John Wiley & Sons, publisher, Chapters 5 and 6).

The DNA that codes for naturally-occurring serine protease of the present invention can also be prepared by chemical synthesis. DNA chemical synthesis can be easily performed by a person with ordinary skill in the art by using an automated DNA synthesizer such as the 396 DNA/RNA synthesizer of Applied Biosystems. Thus, a person with ordinary skill in the art can easily synthesize DNA of the nucleotide sequence indicated in Figs. 1 to 6 (SEQ ID NO: 3) or Figs. 7 to 12 (SEQ ID NO: 5).

A DNA that codes for naturally-occurring serine protease according to codons that differ from the native codons can also be prepared by chemical synthesis as mentioned above, and can also be obtained in accordance with conventional methods such as site-directed mutagenesis using a mutagenic primer with DNA or RNA having the nucleotide sequence indicated in Figs. 1 to 6 (SEQ ID NO: 3) or Figs. 7 to 12 (SEQ ID NO: 5) as a template (see, for example, Current Protocols in Molecular Biology, John Wiley & Sons, publisher, Chapter 8).

In this manner, once the amino acid sequence is determined, various variant forms of serine protease can be designed and produced, including polypeptides in which one or more amino acids are added to the naturally-occurring amino acid sequence while maintaining serine

protease activity, polypeptides in which one or more amino acids are deleted from the above-mentioned naturally-occurring amino acid sequence while maintaining serine protease activity, polypeptides in which one or more amino acids in the above-mentioned naturally-occurring amino acid sequence are substituted with another amino acids while maintaining serine protease activity, and modified polypeptides in which the above-mentioned amino acid addition modification, amino acid deletion modification and amino acid substitution modification are combined, while maintaining serine protease activity.

Although there are no particular restrictions on the numbers of amino acids in the above-mentioned modification including amino acid addition, deletion or substitution modification, with respect to addition, the number of amino acids is dependent on the number of amino acids of known functional protein, e.g. maltose-binding protein, used to form a hybrid protein with the serine protease of the present invention for the purpose of extraction, purification or stabilization or on that of proteins having various physiological activities or the signal peptide added to the present serine protease. Namely, the number of amino acids to be modified is determined depending on the purpose of said modification, and for example, 1 to 50, and preferably 1 to 10, are added.

In addition, with respect to deletion, the number of amino acids that are deleted is designed and determined so as to maintain serine protease activity, and is, for example, 1 to 30, and preferably 1 to 20, or may be, for example, the number of amino acids in a region other than the active region of the present serine protease. Moreover, with respect to substitution, the number of amino acids that are substituted is designed and determined so as to maintain the serine protease activity, and is, for example, 1 to 10, and preferably 1

to 5.

In addition, the present invention provides a serine protease domain comprising the amino acid sequence from amino acid No. 517 to 761 or No. 578 to 822 indicated in Figs. 1 to 6 (SEQ ID NO: 4) or Figs. 7 to 12 (SEQ ID NO: 6), respectively, a kringle domain comprising the amino acid sequence from amino acid No. 85 to 157 or from No. 40 to 112 indicated in Figs. 1 to 6 (SEQ ID NO: 4) or Figs. 7 to 12 (SEQ ID NO: 6), respectively, or scavenger receptor cysteine-rich (SRCR) domains comprising the amino acid sequence from amino acid No. 166 to 266, from No. 273 to 372, from No. 386 to 486, from No. 117 to 217, from No. 227 to 327, from No. 334 to 433 or from No. 447 to 547 indicated in Figs. 1 to 6 (SEQ ID NO: 4) or Figs. 7 to 12 (SEQ ID NO: 6), respectively. Production of these domains can be performed by the method described later, a peptide synthesis method which itself is known, or by cleaving said serine protease by a suitable protease. In addition, modified domains that maintain the activity of the domains of the present invention or DNA that code for them can also be similarly produced.

When DNA of the serine protease or domain of the present invention is obtained in the manner described above, a recombinant serine protease or domain can be produced by ordinary gene recombination using the DNA for serine protease or domain. Namely, DNA coding for the serine protease or domain of the present invention is inserted into a suitable expression vector, said expression vector is introduced into suitable host cells, said host cells are cultured, and the target serine protease or domain is recovered from the resulting culture (cells or medium).

The serine protease or domain of the present invention may be obtained in a biochemically or chemically modified form, such as acylation of its N-terminal, including formylation, acetylation or other C₁₋₆ acylation or deletion. The secretion efficiency and

expression level of the expression system may be improved by addition or modification of a signal sequence, or selection of host. Examples of addition and modification of signal sequence include a method in which a gene
5 coding for a signal peptide of another structural peptide is ligated upstream of the 5'-end of the structural gene of the serine protease or domain of the present invention through a gene coding for a cleavable partial peptide. Specific examples of this include methods using the
10 signal sequence of the trypsin gene and using a gene coding for an enterokinase recognition sequence, as described in Example 4.

Prokaryotic or eukaryotic organisms can be used for the host. Examples of prokaryotes that can be used
15 include bacteria, and particularly Escherichia coli and the genus Bacillus such as Bacillus subtilis. Examples of eukaryotes that can be used include yeast such as the genus Saccharomyces such as Saccharomyces cerevisiae, and other eukaryotic microorganisms, insect cells such as
20 armyworm cells (Spodoptera frugiperda), cabbage looper cells (Trichoplusia ni) and silkworm cells (Bombyx mori), and animal cells such as human cells, monkey cells and mice cells, specific examples of which include COS-1 cells, Vero cells, CHO cells, L cells, myeloma cells,
25 C127 cells, BALB/c3T3 cells and Sp-2/O cells. Organisms themselves can also be used in the present invention, including insects such as cabbage looper and silkworm.

Examples of expression vectors that can be used include plasmids, phages, phagemids and viruses
30 (Baculovirus (insects), Vaccinia virus (animal cells)) etc. A promoter in an expression vector is selected dependent on the host cells, and examples of bacterial promoters that are used include lac promoter and trp promoter, while examples of yeast promoters that are used
35 include adhI promoter and pgk promoter.

In addition, examples of insect promoters include Baculovirus polyhedrin promoter, while examples of animal

cell promoters include Simian Virus 40 early or late promoter, CMV promoter, HSV-TK promoter and SR α promoter. In addition, it is preferable to use an expression vector containing an enhancer, splicing signal, poly A addition signal, selective marker (such as dihydrofolate reductase gene (methotrexate-resistant) or neo gene (G418-resistant) in addition to those indicated above. Furthermore, in case of using an enhancer, SV40 enhancer, for example, is inserted upstream or downstream from the gene.

Transformation of host with an expression vector can be performed in accordance with conventional methods well known in the art, and these methods are described in, for example, Current Protocols in Molecular Biology, John Wiley & Sons, publisher. Culturing of the transformant can also be performed in accordance with conventional methods. Purification of serine protease or domain from the culture can be performed in accordance with conventional methods for isolation and purification of proteins, examples of which include ultrafiltration and various types of column chromatography such as chromatography using Sepharose.

Since the serine protease or domain of the present invention thus obtained is a functional protein, it provides a useful means for pathological analysis, allows screening of physiologically active substances using this protein, and is useful in research searching for therapeutic agents for various diseases. As a specific example of a screening method, screening for example of serine protease inhibitor, can be performed in the same manner as Example 4 by measuring a physiological activity of a tested sample, for example, a naturally-occurring component such as a peptide, protein, non-peptide compound, synthetic compound or fermentation product or compounds obtained from the culture supernatant of various cells, or artificial component an such as various types of synthetic compounds.

In addition, the above-mentioned measurement of physiological activity, measurement of binding affinity and so forth using the serine protease, domain or their partial peptides of the present invention or hosts transformed by DNA coding for the above-mentioned serine protease, domain or their partial peptides or its cell membrane fraction are also preferable embodiments of the screening method of the present invention.

In addition, DNA coding for the serine protease, domain or their partial peptides of the present invention is provided as a useful means of supplementary therapy by administration of the recombinant protein, the gene-expression promotion or inhibition therapy using the sense or antisense method, and elucidation of physiological functions within the body, and is also used for screening of new drugs based on the resulting information.

Moreover, the serine protease, domain or their partial peptides of the present invention, or DNA coding for them can be provided as a kit in a form that can be used when carrying out the above-mentioned screening methods.

Examples of partial peptides include peptide fragments comprising specific region of serin protase of the present invention such as peptide fragments present in the vicinity of a serine residue of an active site as well as peptide fragments that can be antibody recognition sites specific for the serine protease or domain of the present invention. Furthermore, production of said partial peptides can be performed by the methods previously described with respect to the serine protease or domain of the present invention, a peptide synthesis method which is itself known, or by cleaving said serine protease or domain with a suitable protease.

In addition, the above-mentioned cell membrane fraction refers to the fraction containing a large amount of cell membrane obtained after culturing host cells that

allow expression of DNA coding for the serine protease, domain or its partial peptides of the present invention, under conditions that allow expression, and disrupting the resulting host cells containing serine protease, domain or its partial peptides by a method which is itself known.

A screening method for physiologically active substances using the serine protease, domain or its partial peptides of the present invention is performed by screening samples to be tested using the serine protease, domain or its partial peptides of the present invention, DNA coding for them, host cells containing said serine protease, domain or its partial peptides, or its cell membrane fraction. As a specific example of such method, screening is performed by measuring activity or measuring binding affinity using a substrate of the serine protease, domain or its partial peptides of the present invention, examples of which include a synthetic substrate such as a color-development substrate, or a substrate labeled with a radioisotope.

Furthermore, in the case of using host cells containing serine protease, domain or their partial peptides, the cells can be used after fixing with a known method (with glutaraldehyde, formaldehyde, etc.). In addition, in the case of using DNA coding for said serine protease, domain or their partial peptides, a technique for evaluating promotion or inhibition of gene expression can be performed using a reporter gene such as luciferase gene.

Examples

Example 1. Cloning of Novel Serine Protease Motif cDNA for Use as a Probe

(1) PCR Using a Serine Protease Conservative Region

Preparation of mouse brain mRNA was performed using an RGT-T-primed first-strand kit (Pharmacia) in accordance with the attached instructions. 2 μ l (1 μ g)

of oligo-dT primer was added to 5 μ l (about 6 μ g) of the resulting mRNA and heated for 10 minutes at 70°C followed by cooling rapidly on ice.

4 μ l of 5x first strand buffer (250 mM Tris-HCl, pH 8.3, 375 mM KCl, 15 mM MgCl₂), 1 μ l of 10 mM dNTP, 2 μ l of 0.1 M DTT, diethylpyrocarbonate (DEPC)-treated distilled water and 5 μ l (1000 U) of Super Script IIRT were added to the denatured mRNA, and allowed to react for 1 hour at 37°C. PCR was then performed using the serine protease conservative region and the resulting first strand cDNA as the template.

Oligomer KY185 (5'-GTG CTC ACN GCN GCB CAY TG-3') shown in SEQ ID NO: 1 and synthesized based on the amino acid conservative region in the vicinity of an active residue (His) (N-Val-Leu-Thr-Ala-Ala-His-Cys), and oligomer KY189 (3'-CCV CTR AGD CCN CCN GGC GA-5') shown in SEQ ID NO: 2 and synthesized based on the amino acid preservation region in the vicinity of an active residue (Ser) (N-Gly-Asp-Ser-Gly-Gly-Pro-Leu), were used as primers. After performing PCR using Taq DNA polymerase (Amersham), the PCR reaction solution was subcloned to pCRII vector (Invitrogen).

(2) Isolation and Purification of Mouse Brain mRNA for Screening
Preparation of mouse brain mRNA was performed using the Fast Track mRNA Isolation Kit (Invitrogen) in accordance with the attached instructions. Namely, 15 ml of lysis buffer was added to the entire extracted mouse brain and homogenized immediately with a teflonhomogenizer. After passing the homogenized tissue through a 21 gauge injection needle three times using a syringe, it was placed in a 50 ml centrifuge tube and incubated for 1 hour in a water bath at 45°C.

After incubation, the homogenized tissue was centrifuged for 5 minutes at 4000 x g, and the resulting supernatant was transferred to another 50 ml centrifuge

664250" 464760

tube. After adding 950 μ l of 5 M NaCl solution, the solution was again passed through a 21 gauge injection needle three times using a syringe. Next, 1 tablet of oligo(dT) cellulose was added to the solution and after
5 allowing to swell for 2 minutes, the solution was slowly rocked for 1 hour. One hour later, the solution was centrifuged for 5 minutes at 2,000 x g and after aspirating off the supernatant, the precipitate was suspended in 20 ml of binding buffer followed by washing
10 the centrifuged residue in 10 ml of binding buffer.

Next, the precipitate was washed three times with 10 ml of low salt washing solution. After the final washing, the oligo(dT) cellulose was suspended in 800 μ l of low salt washing solution, placed in a spin column,
15 and centrifugal washing was repeated three times for 10 seconds at 5000 x g. After washing, 200 μ l of elution buffer were added followed by repeating centrifugation for 10 seconds at 5000 x g twice to obtain 400 μ l of mRNA solution. mRNA was recovered from the mRNA solution by
20 ethanol precipitation in accordance with conventional methods, and dissolved in 20 μ l of DEPC-treated distilled water.

(3) Screening from a cDNA Library

<Step 1> Synthesis of cDNA

25 2 μ l (1 μ g) of oligo dT NotI primer was added to 5 μ l (about 6 μ g) of the mRNA obtained in Example 1, part (2), and heated for 10 minutes at 70°C followed by cooling rapidly on ice. 4 μ l of 5x first strand buffer (250 mM Tris-HCl pH 8.3, 375 mM KCl, 15 mM MgCl₂), 1 μ l
30 of 10 mM dNTP, 2 μ l of 0.1 M DTT, DEPC-treated distilled water and 5 μ l (1000 U) of Super Script IIRT were added to this denatured mRNA and allowed to react for 1 hour at 37°C.

Next, 91 μ l of DEPC-treated distilled water, 30 μ l of 5x second strand buffer (100 mM Tris-HCl pH 6.9, 450 mM KCl, 23 mM $MgCl_2$, 0.75 mM β -NAD⁺, 50 mM $(NH_4)_2SO_4$), 3 μ l of 10 mM dNTP, 1 μ l (10 U) of *E. coli* DNA ligase, 4 μ l (40 U) of *E. coli* DNA polymerase and 1 μ l (2 U) of *E. coli* RNAase H were added to this reaction solution, and after reacting for 2 hours at 16°C, 2 μ l (10 U) of T4 DNA polymerase was added and allowed to react for 5 minutes at 16°C.

Moreover, 10 μ l of 0.5 M EDTA was added to this solution and after mixing, 150 μ l of phenol:chloroform:isoamyl alcohol (25:24:1) was added. After stirring, the solution was centrifuged for 5 minutes at 15,000 rpm and the supernatant was recovered. 10 μ l of 5 M KOAc and 400 μ l of ethanol were added to the resulting supernatant followed by stirring and centrifuging for 10 minutes at 15,000 rpm. The precipitate obtained by centrifugation was washed with 500 μ l of 70% ethanol and after gently air drying, was dissolved in 25 μ l of DEPC-treated distilled water.

<Step 2> Addition of EcoRI Adapter

10 μ l of 5 x T4 DNA linking buffer (250 mM Tris-HCl pH 7.6, 50 mM $MgCl_2$, 5 mM ATP, 5 mM DTT, 25% (W/v) PEG 8000), 10 μ l (10 μ g) of EcoRI adapter solution and 5 μ l (5 U) of T4 DNA ligase were added to 25 μ l of the double strand cDNA obtained in the previous step. After reacting for 16 hours at 16°C, 50 μ l of phenol:chloroform:isoamyl alcohol (25:24:1) was added, stirred and centrifuged for 5 minutes at 15,000 rpm followed by recovery of the supernatant. 5 μ l of 5 M KOAc and 125 μ l of ethanol were added to the recovered supernatant and stirred. After cooling for 20 minutes at

-80°C, the supernatant was centrifuged for 10 minutes at 15,000 rpm. The precipitate resulting from centrifugation was washed with 200 µl of 70% ethanol and after gently air-drying, was dissolved in 40 µl of DEPC-treated distilled water.

<Step 3> Ligation with λgt 10

1 µl (50 ng) of λgt 10 (EcoRI fragment) was added to 3 ml of size-fractionated cDNA solution followed by the addition of 11 µl of DEPC-treated distilled water, 4 µl of 5 x T4 DNA linking buffer and 1 µl of 5 x T4 DNA ligase and allowing to react for 3 hours at room temperature. After extracting with phenol:chloroform:isoamyl alcohol (25:24:1), adding 5 µl (5 µg) of yeast tRNA, 5 µl of 5 M KOAc and 125 µl of ethanol and stirring, the mixture was cooled for 20 minutes at -80°C and centrifuged for 10 minutes at 15,000 rpm. The precipitate resulting from centrifugation was washed with 200 µl of 70% ethanol and after gently air-drying, was dissolved in 5 µl of TE (10 mM Tris-HCl pH 8.0, 1 mM EDTA).

<Step 4> Packaging

The ligated cDNA obtained in step 3 was packaged using Gigapack Packaging Extracts (Stratagene). Namely, after adding 10 µl of Freeze-thaw Extract contained in the kit to 1 µl of 0.1 µg/µl ligated cDNA, 15 µl of Sonic Extract contained in the kit was immediately added and mixed well. After allowing to stand for 2 hours at room temperature, 500 µl of phage dilution buffer (100 mM NaCl, 10 mM MgSO₄, 50 mM Tris-HCl pH 7.5, 0.01% gelatin) was added followed by addition of 20 µl of chloroform. After mixing well, the mixture was centrifuged for 5 minutes at the room temperature at 15,000 rpm and the supernatant was recovered to obtain a phage solution.

According to conventional methods, it was used to infect the host E. coli after titrating the phase solution.

<Step 5> Library Screening

The DNA fragment obtained in Example 1, part (1) was
5 labeled with α -³²P dCTP using the BcaBest DNA labeling
kit (Takara) to prepare a probe. A cDNA library
comprising approximately 400,000 clones obtained in the
previous step was screened using this probe. As a
10 result, the longest clone of the inserted DNA fragment,
pUC18/MBSSP-3/1-1 was obtained from the approximately
400,000 clones.

The total length of the pUC18/MBSSP-3/1-1 cDNA was
2,597 base pairs, and consisted of a 5' non-translation
15 region of 244 base pairs, a translation region of 2283
base pairs, and a 3' non-translation region of 70 base
pairs. The translation region was determined to code for
a novel functional protein containing not only a serine
protease domain (amino acid No. 517 to 761), but also a
kringle domain (amino acid No. 85 to 157) and three
20 scavenger receptor cysteine-rich domains (amino acid No.
166 to 266; domain 1, amino acid No. 273 to 372; domain
2, and amino acid No. 386 to 486; domain 3). The
nucleotide sequence and corresponding amino acid sequence
of pUC18/MBSSP-3/1-1 cDNA are shown in Figs. 1 to 6 (SEQ
25 ID NO: 3).

Example 2. Examination of Expression Site of MBSSP-3
by Northern Blotting

Mouse brain total RNA was prepared using Trizol
reagent (Life Technology) in accordance with the attached
30 instructions. Namely, after extracting mouse cerebrum,
brain stem, cerebellum and medulla oblongata, the tissues
were immediately homogenized with a Polytron
(Kinematica), and the tissues were lysed by addition of
10 volumes (approx. 3 ml) of Trizol reagent relative to
35 tissue volume. Moreover, 600 μ l of chloroform was added,
followed by mixing and centrifuging for 15 minutes at 4°C
and 15,000 rpm. After centrifugation, the aqueous phase

was recovered and 1500 μ l of isopropanol was added to the recovered aqueous phase, followed by mixing and centrifuging for 30 minutes at 4°C and 15,000 rpm.

After dissolving the resulting total RNA precipitate of each site of mouse brain in 400 μ l of DEPC-treated distilled water, it was blotted onto a membrane filter in accordance with conventional methods. Next, pUC18/mBSSP-3/1-1 was digested with restriction enzyme EcoRI, followed by isolation and purification of an approximately 2.7 kbp DNA fragment to prepare a probe by labeling with α -³²P dCTP using the above-mentioned method.

After hybridizing this probe overnight at 55°C with the membrane filters blotted with the total RNA prepared from each of the mouse brain sites described above, and with membrane filters blotted with commercially available mRNA prepared from various organs (Clontech), each of the membrane filters was washed for 20 minutes at room temperature with 2 x SSC containing 1% SDS (150 mM NaCl, 15 mM sodium citrate), and then washed twice for 30 minutes at 65°C after changing to 0.1 x SSC and 0.1% SDS. The membrane filters were then exposed for 30 minutes on a BAS2000 imaging plate (Fuji Photo Film).

The results are shown in Fig. 13. With respect to expression in each organ, expression was confirmed in the brain, lung and kidney. With respect to each site of the brain, strong expression was observed in the cerebrum and brain stem. Although weak expression was also observed in the medulla oblongata, expression was not observed in the cerebellum. The expressed size was only about 2.7 kbp in all cases.

Example 3 Cloning of Human BSSP-3 cDNA

Human brain cDNA library was purchased from Clontech. Mouse BSSP-3 cDNA fragment was fluorescent labeled using glutaraldehyde to prepare a probe.

pUC18/hBSSP-3 was obtained as a result of screening the human brain cDNA library comprising approximately 400,000 clones using this probe.

5 The translation region of pUC18/hBSSP-3 cDNA was determined to code for a functional protein containing not only a serine protease domain (amino acid No. 578 to 822), but also a kringle domain (amino acid No. 40 to 112) and four scavenger receptor cysteine-rich domains (amino acid No. 117 to 217: domain 1, amino acid No. 227 to 327: domain 2, amino acid No. 334 to 433: domain 3, 10 and amino acid No. 447 to 547: domain 4) in the same manner as mouse BSSP-3 cDNA.

However, it was clearly different from that predicted from the primary structure of mouse BSSP-3 15 cDNA. In contrast to mouse BSSP-3 having three scavenger receptor cysteine-rich domains, human BSSP-3 was determined to have four such domains. The nucleotide sequence and corresponding amino acid sequence of pUC18/hBSSP-3 are shown in Figs. 7 to 12 (SEQ ID NO: 5). 20 pUC18/hBSSP-3 are shown in Figs. 7 to 12 (SEQ ID NO: 5).

Example 4. Measurement of Enzyme Activity of Novel Serine Protease Mature Protein Coded by Human BSSP-3 cDNA

25 (1) Construction of Expression Plasmid
pUC18/hBSSP-3 DNA fragment and pdKCR vector DNA fragment were ligated in accordance with conventional methods, *E. coli* JM109 was transformed, and the resulting colonies were analyzed by PCR to obtain the target serine protease hBSSP-3 expression plasmid pdKCR/hBSSP-3.

30 Next, primers were designed by amplifying genes coding for the signal sequence following the starting methionine of trypsin II and enterokinase recognition sequence so that EcoRI restriction enzyme recognition site was added upstream from the 5' side and BspMI 35 restriction enzyme recognition site was added downstream from the 3' side. Using these primers, PCR was performed using pCR/Trypsin II plasmid for a template, and the product was digested with restriction enzymes (EcoRI and

BspMI), followed by isolation and purification of an approximately 75 bp DNA fragment. Similarly, using a primer designed so that a BspMI restriction enzyme recognition site is added upstream from DNA coding for a mature protein of human BSSP-3, PCR was performed using pdKCR/hBSSP-3 for the template, followed by digestion of the product with restriction enzymes (BspMI and Bpu1102I) and isolation and purification of the DNA fragment.

Next, a resulting DNA fragment coding for trypsin II signal sequence and enterokinase recognition site, and a DNA fragment coding for human BSSP-3 mature protein were ligated into pdKCR/hBSSP-3 vector predigested with restriction enzymes (BspMI and Bpu1102I) in accordance with conventional methods, followed by transformation of E. coli JM109. Transformed colonies containing the target chimeric DNA were confirmed by PCR to obtain the expression plasmid (pdKCR/Trp-hBSSP-3).

(2) Expression in COS-1 Cells

Chimeric gene DNA prepared in Example 4, part (1) was transfected into COS-1 cells using lipofectin (Life Technologies). Namely, 5×10^5 COS-1 cells were grown in Dalvecco's minimum essential medium (DMEM, Nissui Pharmaceutical) containing 10% fetal bovine serum in 10 cm diameter culture dishes (Corning, 430167). On the following day, after rinsing the cells with 5 ml of Opti-MEM medium (Life Technologies), 5 ml of fresh Opti-MEM medium was added, followed by culturing for 2 hours at 37°C.

After culturing, a mixture of 1 µg of the above-mentioned plasmid and 5 µg of lipofectin was added to each dish, followed by culturing for 5 hours at 37°C. After culturing, 5 ml of Opti-MEM medium was added to make a total volume of 10 ml, followed by additional culturing for 72 hours at 37°C. After culturing, the culture supernatant was collected by centrifugation to

prepare samples for measurement of enzyme activity. In addition, culture supernatant was prepared for use as a control by transfecting only expression plasmid pdKCR into COS-1 cells.

5 (3) Measurement of Enzyme Activity

 The enzyme activity in the culture supernatant obtained in Example 4, part (2) was measured. Namely, 5 μ l of enterokinase (10 mg/ml, Biozyme Laboratories) was mixed with 45 μ l of culture supernatant of COS-1 cells and allowed to react for 2 hours at 37°C. Next, 50 μ l of 0.2 mM substrate solution prepared by dissolving synthetic substrate Boc-Phe-Ser-Arg-MCA (Peptide Research) in DMSO and diluted with 0.1 M Tris-HCl, pH 8.0 was added and allowed to react for 16 hours at 4°C.

10 After reacting, fluorescence was measured at an excitation wavelength of 485 nm and fluorescent wavelength of 535 nm. As a result, enzyme activity was only observed when culture supernatant of COS-1 cells that expressed Trp-hBSSP-3 were digested with enterokinase.

20 Based on the above results, the serine protease domain of human BSSP-3 was determined to be a functional protein having enzyme activity.

25 Effect of the Invention

 The inventors of the present invention isolated mouse BSSP-3 cDNA from mouse brain cDNA library, that codes for a novel functional protein containing not only a novel serine protease domain, but also a novel kringle domain and novel scavenger receptor cysteine-rich domains. The isolated mouse BSSP-3 cDNA coded for 1 Kringle domain, 3 scavenger receptor cysteine-rich domains and 1 serine protease domain. In addition, as a result of examining the expression sites of the isolated mouse BSSP-3 mRNA, the inventors of the present invention determined that mouse BSSP-3 mRNA is strongly expressed

in the brain, and particularly strongly in the cerebrum and brain stem.

Next, the inventors of the present invention succeeded at isolating human BSSP-3 cDNA from a human brain cDNA library using mouse BSSP-3 cDNA as a probe. As a result, the inventors of the present invention determined that human BSSP-3 cDNA is clearly different from that predicted from the primary structure of mouse BSSP-3 cDNA, in that it was determined to code for 1 kringle domain, 4 scavenger receptor cysteine-rich domains, and 1 serine protease domain.

Moreover, the inventors of the present invention determined that, when human BSSP-3 cDNA coding for serine protease mature protein was expressed in COS-1 cells, the expression product is a functional protein having enzyme activity. Not only was the novel functional protein in the present invention determined to have complex functions in terms of its primary structure, but that it plays a constant role in the physiological functions in the brain through the complex functions. Thus, the mouse BSSP-3 cDNA and novel functional protein encoded by the mouse BSSP-3 cDNA of the present invention provide useful means of pathological analysis of various types of mouse disease models.

In addition, the human BSSP-3 cDNA and novel functional protein encoded by the human BSSP-3 cDNA of the present invention provide means for screening therapeutic agents for various diseases based on the useful information for disease treatment obtained through the above pathological analysis. Moreover, they can also be applied to actual development of therapeutic drugs for human diseases. Examples of such treatment methods include supplementary therapy by administration of the recombinant protein and gene-expression promotion or inhibition therapy using the sense or antisense method.

Moreover, the structure of each domain of the novel functional proteins can also function independently.

Thus, molecules that demonstrate interaction with each domain structure can be specified after separately expressing each domain structure. In addition, supplementary therapy by administration of the recombinant protein and the gene-expression promotion or inhibition therapy using the sense or antisense method can be performed by investigating the involvement of the specified molecular group in a disease.

5

CLAIMS

1. A serine protease or its partial peptide comprising an amino acid sequence identical to serine protease indicated in SEQ ID NO: 6, an amino acid
5 sequence in which a portion of the identical amino acid sequence is deleted or substituted, or an amino acid sequence in which at least one amino acid is added to the identical amino acid sequence or an amino acid sequence in which a portion of the identical amino acid sequence
10 is deleted or substituted.
2. A serine protease domain or its partial peptide comprising an amino acid sequence identical to a serine protease domain comprising the amino acid sequence from amino acid No. 578 to 822 indicated in SEQ ID NO: 6, an
15 amino acid sequence in which a portion of the identical sequence is deleted or substituted, or an amino acid sequence in which at least one acid is added to the identical amino acid sequence or an amino acid sequence in which a portion of the identical amino acid sequence
20 is deleted or substituted.
3. A kringle domain or its partial peptide comprising an amino acid sequence identical to a kringle domain comprising the amino acid sequence from amino acid No. 40 to 112 indicated in SEQ ID NO: 6, an amino acid
25 sequence in which a portion of the identical sequence is deleted or substituted, or an amino acid sequence in which at least one amino acid is added to the identical amino acid sequence or an amino acid sequence in which a portion of the identical amino acid sequence is deleted
30 or substituted.
4. A scavenger receptor cysteine-rich (SRCR) domain or its partial peptide comprising an amino acid sequence identical to an SRCR domain comprising the amino acid sequence from amino acid No. 117 to 217, from amino
35 acid No. 227 to 327, from amino acid No. 334 to 433, or from amino acid No. 447 to 547 indicated in SEQ ID NO: 6, an amino acid sequence in which a portion of the

identical sequence is deleted or substituted, or an amino acid sequence in which at least one amino acid is added to the identical amino acid sequence or an amino acid sequence in which a portion of the identical amino acid sequence is deleted or substituted.

5 5. DNA which codes for the serine protease, domain or their partial peptides as claimed in any one of the above-mentioned claims 1 to 4.

10 6. DNA which codes for a peptide having serine protease, domain or their partial peptide activity, and is hybridizable with DNA that codes for the serine protease, domain or their partial peptides as claimed in any one of the above-mentioned claims 1 to 4 under stringent conditions.

15 7. An expression vector containing the DNA as claimed in claims 5 or 6.

8. A host transformed by the expression vector as claimed in claim 7.

20 9. A process for preparing serine protease, domain or their partial peptides comprising culturing or breeding a host as claimed in claim 8, and recovering serine protease, domain or their partial peptides.

25 10. An antibody whose antigen is the serine protease, domain or their partial peptides as claimed in any one of claims 1 to 4.

11. A process for screening physiologically active substances that uses the serine protease, domain or their partial peptides as claimed in any one of claims 1 to 4, or the DNA as claimed in claims 5 or 6.

ABSTRACT

The present invention discloses a serine protease or
its partial peptide containing an amino acid sequence
5 identical to serine protease indicated in SEQ ID NO: 6,
an amino acid sequence in which a portion of the
identical amino acid sequence is deleted or substituted,
or an amino acid sequence in which at least one amino
acid is added to the identical amino acid sequence or an
10 amino acid sequence in which a portion of the identical
amino acid sequence is deleted or substituted.

0449 0249

Fig.1

CGAGGGTGGGTGGAGGTCGGACTCCGGGCTACAGAGCTCCTGGGCTCATCGCCTCTGG 60
CTCCAGCCCTTTGCTTCGGGGGCTGACCCCTTTGGGTCCCGGTGATCCTCCAGCTGCC 120
CGGGGGCTGGGACACAGAGGGGGGGCGGAGCGGTGGAGGGGGCTCTAGGACTCTGCCG 180
GCCCGCCCCCGCCCTCCCGGGGACCCGGAGCCAGCATGACACACTCGCGCGCCGC 240
AGCC 244
ATGGCGCTCGCCCCGCTGCGTGGCTGTGATTTAGGGGCACGTCTGTAGTGGCC 301
MetAlaLeuAlaArgCysValLeuAlaValIleLeuGlyAlaLeuSerValValAla 19

CGCGCTGATCCGGTCTCGCGCTCTCCCTTCACCGCCCGCATCCGTCCACCGGCTTCC 361
ArgAlaAspProValSerArgSerProLeuHisArgProHisProSerProProArgSer 39

CAACACGGCACTACCTTCCAGCTCGCGGGGCCACCCAGGACCCCGCGCTTCCCGCTC 421
GlnHisAlaHisTyrLeuProSerSerArgArgProProArgThrProArgPheProLeu 59

CCGCTGCGGATCCCCGCTGCCAGCGCCCGCAGGTCTCTCAGCACCGGGGCACACGCCCC 481
ProLeuArgIleProAlaAlaGlnArgProGlnValLeuSerThrGlyHisThrProPro 79

ACGATTCCACGCCGCTGCGGGGCAGGAGAGTCGTGGGGCAATGCCACCAACCTCGGCGTC 541
ThrIleProArgArgCysGlyAlaGlyGluSerTrpGlyAsnAlaThrAsnLeuGlyVal 99

CCGTGCTACACTGGGACGAGGTGCCGCCCTTCTGGAGCGGTCCGCCCGCCAGTTGG 601
ProCysLeuHisTrpAspGluValProProPheLeuGluArgSerProProAlaSerTrp 119

Fig.2

GCTGAGTGGAGGGCAGCCGACAACTTCTGCCGGAGCCCGATGGCTCGGCAGACCTT	661
AlaGluLeuArgGlyGlnProHisAsnPheCysArgSerProAspGlySerGlyArgPro	139
TGGTGCTTCTATCGGAATGCCCAGGGCAAGTAGACTGGGGCTACTGCGATTGTGTGTCAA	721
TrpCysPheTyrArgAsnAlaGlnGlyLysValAspTrpGlyTyrCysAspCysGlyGln	159
GGCCCCGGCGTTGCCCGTCATTCGCCCTTCTTGGTGGGAACAGTGGGCATGAAGTTCGAGTG	781
GlyProAlaLeuProValIleArgLeuValGlyGlyAsnSerGlyHisGluGlyArgVal	179
GAGCTGTACCAACGCTGGCCAGTGGGGACCATCTGTGACGACCAATGGGACAAATGCAGAC	841
GluLeuTyrHisAlaGlyGlnTrpGlyThrIleCysAspAspGlnTrpAspAsnAlaAsp	199
GCAGACGTCATCTGTAGGCAGCTGGGGCTCAGTGGCATTGCCAAAGCATGGCATCAGGCA	901
AlaAspValIleCysArgGlnLeuGlyLeuSerGlyIleAlaLysAlaTrpHisGlnAla	219
CATTTTGGGAAGGATCTGGCCCAATATTGTTGGATGAAGTACGCTGCACCCGGAACGAG	961
HisPheGlyGluGlySerGlyProIleLeuLeuAspGluValArgCysThrGlyAsnGlu	239
CTGTCAATTGAGCAATGTCCAAAGAGTTCCTGGGGCGAACATACTGTGGCCATAAAGAA	1021
LeuSerIleGluGlnCysProLysSerSerTrpGlyGluHisAsnCysGlyHisLysGlu	259

Fig.3

GATGCTGGAGTGCTGTGTCTCTTAACAGATGGTGTTCATCAGACTGGCAGGAGGAAA	1081
AspAlaGlyValSerCysValProLeuThrAspGlyValIleArgLeuAlaGlyGlyLys	279
AGTACCCATGAAGGTCGCCTGGAGGTCTACTACAAGGGCAGTGGGGGACAGTCTGTGAT	1141
SerThrHisGluGlyArgLeuGluValTyrTyrLysGlyGlnTrpGlyThrValCysAsp	299
GATGGCTGGACTGAGATGAACACATACGTGGCTTGTGCGACTGCTGGGATTAAATACGGC	1201
AspGlyTrpThrGluMetAsnThrTyrValAlaCysArgLeuLeuGlyPheLysTyrGly	319
AAACAGTCCTCTGTGAACCATTTTGATGGCAGCAACAGGCCCATATGGCTGGATGACGTC	1261
LysGlnSerSerValAsnHisPheAspGlySerAsnArgProIleTrpLeuAspAspVal	339
AGCTGCTCAGGAAAAGAGTCAGCTTCATTCAGTGTTCACAGGAGACAGTGGGGAAGGCAT	1321
SerCysSerGlyLysGluValSerPheIleGlnCysSerArgArgGlnTrpGlyArgHis	359
GACTGCAGCCATAGAGAAGATGTGGGCCTCACCTGCTATCCTGACAGCGATGGACATAGG	1381
AspCysSerHisArgGluAspValGlyLeuThrCysTyrProAspSerAspGlyHisArg	379
CTTCTCCAGGTTTCCCATCAGACTAGTGGATGGAGAGAATAAGAAGGAAGGACGAGTG	1441
LeuSerProGlyPheProIleArgLeuValAspGlyGluAsnLysLysGluGlyArgVal	399

ω
13

Fig.4

GAGGTTTTGTCAATGGCCAAATGGGGAAACAATCTGCCGATGACGGATGACCCGATAAGCAT	1501
GluValPheValAsnGlyGlnTrpGlyThrIleCysAspGlyTrpThrAspLysHis	419
GCAGCTGTGATCTGCCGGCAGCTTGGCTATAAGGGTCCTGCCAGAGCAAGGACTATGGCT	1561
AlaAlaValIleCysArgGlnLeuGlyTyrLysGlyProAlaArgAlaArgThrMetAla	439
TATTTTGGGGAAGGAAAGGCCCCCATCCACATGGATAATGTGAAGTGCACAGGAAATGAG	1621
TyrPheGlyGluGlyLysGlyProIleHisMetAspAsnValLysCysThrGlyAsnGlu	459
AAGCCCTGGCTGACTGTGTCAAACAAGACATTTGGAAGGCACAACTGCCGCCACAGTGAG	1681
LysAlaLeuAlaAspCysValLysGlnAspIleGlyArgHisAsnCysArgHisSerGlu	479
GATGCAGGAGTCATCTGTGACTATTAGAGAAGAAAGCATCAAGTAGTGGTAATAAAGAG	1741
AspAlaGlyValIleCysAspTyrLeuGluLysLysAlaSerSerSerGlyAsnLysGlu	499
ATGCTCTCATCTGGATGTGGACTGAGGTTACTGCACCCGTCCGAGAAACGGATCATTTGGT	1801
MetLeuSerSerGlyCysGlyLeuArgLeuLeuHisArgArgGlnLysArgIleIleGly	519
GGGAACAATTCTTTAAGGGTGCCCTGGCCCTTGGCAGGCTTCCCTCAGGCTGAGGTCGGCC	1861
GlyAsnAsnSerLeuArgGlyAlaTrpProTrpGlnAlaSerLeuArgLeuArgSerAla	539

Fig.5

CATGGAGACGGCAGGCTGCTTTGTGGAGCTACCCCTTCTGAGTAGCTGCTGGTCTCTGACA	1921
HisGlyAspGlyArgLeuLeuCysGlyAlaThrLeuLeuSerSerCysTrpValLeuThr	559
GCTGCACACTGCTTCAAAAAGGTACGGAACAACACTCGAGGAGCTATGCAGTTCGAGTTGGG	1981
AlaAlaHisCysPheLysArgTyrGlyAsnAsnSerArgSerTyrAlaValArgValGly	579
GATTATCATACTCTGGTACCAGAGGAGTTTGAACAAGAAATAGGGGTTC AACAGATTGTG	2041
AspTyrHisThrLeuValProGluGluPheGluGlnGluIleGlyValGlnGlnIleVal	599
ATTACAGGAACTACAGGCCAGACAGAACCGACTATGACATTGCCCTGGTTAGATTGCAA	2101
IleHisArgAsnTyrArgProAspArgSerAspTyrAspIleAlaLeuValArgLeuGln	619
GGACCAGGGAGCAATGTGCCAGACTAAGCACCCACGTTTGGCCAGCCTGTTTACCTCTA	2161
GlyProGlyGluGlnCysAlaArgLeuSerThrHisValLeuProAlaCysLeuProLeu	639
TGGAGAGAGGGCCACAGAAAACAGCCCTCCAACCTGTACATAACAGGATGGGAGACACA	2221
TrpArgGluArgProGlnLysThrAlaSerAsnCysHisIleThrGlyTyrGlyAspThr	659
GGTCGTGCCTACTCAAGAACTCTACAACAAGCTGTGTGCCTCTGTACCCCAAGAGGTTT	2281
GlyArgAlaTyrSerArgThrLeuGlnGlnAlaAlaValProLeuLeuProLysArgPhe	679

Fig.6

TGTAAGAGAGGTACAAGGACTATTACTGGGAGAAATGCTCTGTGCTGGGAACCTCCAA	2341
CysLysGluArgTyrLysGlyLeuPheThrGlyArgMetLeuCysAlaGlyAsnLeuGln	699
GAAGACAACCGTGTGGACAGCTGCCAGGGAGACAGTGGAGGACCACATCATGTGTGAAAAG	2401
GluAspAsnArgValAspSerCysGlnGlyAspSerGlyGlyProLeuMetCysGluLys	719
CCTGATGAGTCCTGGGTTGTGTATGGGGTGACTTCCTGGGGGTATGCATGTGGAGTCAAA	2461
ProAspGluSerTrpValValTyrGlyValThrSerTrpGlyTyrGlyCysGlyValLys	739
GACACTCCTGGAGTTTATACCAGAGTCCCCGCCCTTTGTACCTTGGATATAAAGTGTCAAC	2521
AspThrProGlyValTyrThrArgValProAlaPheValProTrpIleLysSerValThr	759
AGTCTGTAACTTATGGAAAGCTCAAGAAAAATAGTAAACAGTAACCATTCAGTCTTCATA	2581
SerLeu***	761
CTTGGCACCATGCCAGAAAAAATAAAAAA	2614

13/05

Fig.7

CCGACGACGGTCCGCCCGCCCTCTCCCGCGCTTCCCGCGCCCCCGGGCGCTCCCT	60
ProThrThrArgProProProProLeuProArgPheProArgProProArgAlaLeuPro	20
GCCAGCGCCCGCACGCCCTCCAGCGCGGCACACGCCCGCGCGCACCCCTGGGGCTGC	120
AlaGlnArgProHisAlaLeuGlnAlaGlyHisThrProArgProHisProTrpGlyCys	40
CCCCCGCGGAGCCATGGGTACGCGTGACGGACTTCGGCGCCCCCGTGCTGCGGTGGCG	180
ProAlaGlyGluProTrpValSerValThrAspPheGlyAlaProCysLeuArgTrpAla	60
GAGGTGCCACCCCTTCCGTGGAGCGGTCCGCCCCCAGCGAGCTGGGCTCAGCTGCGAGGACAG	240
GluValProProPheLeuGluArgSerProProAlaSerTrpAlaGlnLeuArgGlyGln	80
CGCCACAACTTTGTGCGAGCCCCGACGGCGGGCGAGACCCTGGTGTTTCTACGGAGAC	300
ArgHisAsnPheCysArgSerProAspGlyAlaGlyArgProTrpCysPheTyrglyAsp	100
GCCCCGTGGCAAGGTGGACTGGGGCTACTGCGACTGCAGACACGGATCAGTACGACTTCGT	360
AlaArgGlyLysValAspTrpGlyTyrCysAspCysArgHisGlySerValArgLeuArg	120
GGCGGCAAAAATGAGTTTGAAGGCACAGTGGAAAGTATATGCAAGTGGAGTTTGGGGCACT	420
GlyGlyLysAsnGluPheGluGlyThrValGluValTyrAlaSerGlyValTrpGlyThr	140

Fig.8

GTCTGTAGCAGCCACTGGGATGATTCTGATGCATCAGTCATTGTGCACCAGCTGCAGCTG	480
ValCysSerSerHisTrpAspSerAspAlaSerValIleCysHisGlnLeuGlnLeu	160
GGAGGAAAAGGAATAGCAAAACACCCCGTTTCTGGACTGGGCCCTTATTCCCATTTAT	540
GlyGlyLysGlyIleAlaLysGlnThrProPheSerGlyLeuGlyLeuIleProIleTyr	180
TGGAGCAATGTCCGTTGCCGAGGAGATGAAGAAATATACTGCTTTGTGAAAAAGACATC	600
TrpSerAsnValArgCysArgGlyAspGluGluAsnIleLeuLeuCysGluLysAspIle	200
TGGCAGGGTGGGGTGTGTCCTCAGAAGATGGCAGCTGCTGTCACTGTAGCTTTTCCCAT	660
TrpGlnGlyGlyValCysProGlnLysMetAlaAlaValThrCysSerPheSerHis	220
GGCCCAACGTTCCCATCATTCGCCTTGCTGGAGGCAGCAGTGTGCATGAAGCCGGGTG	720
GlyProThrPheProIleIleArgLeuAlaGlyGlySerSerValHisGluGlyArgVal	240
GAGCTCTACCATGCTGGCCAGTGGGGAACCGTTTGTGATGACCAATGGGATGATGCCGAT	780
GluLeuTyrHisAlaGlyGlnTrpGlyThrValCysAspAspGlnTrpAspAlaAsp	260
GCAGAAAGTGATCTGCAGGCAGCTGGGCCCTCAGTGGCATTGCCAAAGCATGGCATCAGGCA	840
AlaGluValIleCysArgGlnLeuGlyLeuSerGlyIleAlaLysAlaTrpHisGlnAla	280

Fig.9

TATTTTGGGAAGGCTCTGGCCAGTTATGTTGGATGAAGTACGCTGCACCTGGGAATGAG 900
 TyrPheGlyGluGlySerGlyProValMetLeuAspGluValArgCysThrGlyAsnGlu 300

 CTTTCAATTGAGCAGTGTCCTCAAGAGCTCCTGGGAGAGCATAACTGTGGCCATAAAGAA 960
 LeuSerIleGluGlnCysProLysSerSerTrpGlyGluHisAsnCysGlyHisLysGlu 320

 GATGCTGGAGTGCTCTGACCCCTCTAACAGATGGGGTCATCAGACTTGCAGGTGGGAAA 1020
 AspAlaGlyValSerCysThrProLeuThrAspGlyValIleArgLeuAlaGlyGlyLys 340

 GGCAGCCATGAGGGTCGCTTGGAGGTATATTACAGAGGCCAGTGGGAACTGTCTGTGAT 1080
 GlySerHisGluGlyArgLeuGluValTyrTyrArgGlyGlnTrpGlyThrValCysAsp 360

 GATGGCTGGACTGAGCTGAATACATACGTGGTTGTGCGACAGTTGGGATTTAAATATGGT 1140
 AspGlyTrpThrGluLeuAsnThrTyrValValCysArgGlnLeuGlyPheLysTyrGly 380

 AAACAAGCATCTGCCAACCATTTTGAAGAAAGCACAGGGCCCATATGTTGGATGACGTC 1200
 LysGlnAlaSerAlaAsnHisPheGluGluSerThrGlyProIleTrpLeuAspVal 400

 AGCTGCTCAGGAAAGGAAACCAGATTTCTCAGTGTTCAGGCGACAGTGGGGAAGGCAT 1260
 SerCysSerGlyLysGluThrArgPheLeuGlnCysSerArgArgGlnTrpGlyArgHis 420

Fig.10

GACTGCAGCCACCGAAGATGTTAGCATGCCTGCTACCTGGCGGCGAGGACACAGG 1320
 AspCysSerHisArgGluAspValSerIleAlaCysTyrProGlyGlyGluGlyHisArg 440
 CTCCTCTCTGGGTTTTCCTGTCAAGACTGATGGATGGAGAAAATAAGAAAGACGAGTG 1380
 LeuSerLeuGlyPheProValArgLeuMetAspGlyGluAsnLysLysGluGlyArgVal 460
 GAGGTTTTTATCAATGGCCAGTGGGGAACAACTCTGTGATGATGGACTGATAAGGAT 1440
 GluValPheIleAsnGlyGlnTrpGlyThrIleCysAspAspGlyTrpThrAspLysAsp 480
 GCAGCTGTGATCTGTCTCAGCTTGGCTACAAGGTCCTGCCAGAGCAAGAACCATGGCT 1500
 AlaAlaValIleCysArgGlnLeuGlyTyrLysGlyProAlaArgAlaArgThrMetAla 500
 TACTTTGGAGAAGGAAAAGGACCCATCCATGTGGATAATGTGAAGTGCACAGGAAATGAG 1560
 TyrPheGlyGluGlyLysGlyProIleHisValAspAsnValLysCysThrGlyAsnGlu 520
 AGGTCCTTGGCTGACTGTATCAAGCAAGATATTGGAAGACACAACTGCCGCCACAGTGAA 1620
 ArgSerLeuAlaAspCysIleLysGlnAspIleGlyArgHisAsnCysArgHisSerGlu 540
 GATGCAGGAGTTATTTGTGATTAATTTGGCAAGAAGCCCTCAGGTAACAGTAATAAAGAG 1680
 AspAlaGlyValIleCysAspTyrPheGlyLysLysAlaSerGlyAsnSerAsnLysGlu 560


Fig.11

TCCCTCTCATCTGTTTGTGGCTTGAGATTACTGCACCGTCGGCAGAGCGGATCATTGGT	1740
SerLeuSerSerValCysGlyLeuArgLeuLeuHisArgArgGlnLysArgIleIleGly	580
GGGAAAAATTCTTTAAGGGGTGGTTGGCCCTTGGCAGGTTTCCCTCCGGCTGAAAGTCATCC	1800
GlyLysAsnSerLeuArgGlyGlyTyrProTrpGlnValSerLeuArgLeuLysSerSer	600
CATGGAGATGGCAGGCTCCTCTGCGGGGCTACGCTCCTGAGTAGCTGCTGGTGGTCCCTCACA	1860
HisGlyAspGlyArgLeuLeuCysGlyAlaThrLeuLeuSerSerCysTrpValLeuThr	620
GCAGCACACTGTTTCAAGAGGTATGGCAACAGCAGCTAGGAGCTATGCTGTAGGGTTGGA	1920
AlaAlaHisCysPheLysArgTyrGlyAsnSerThrArgSerTyrAlaValArgValGly	640
GATTATCATCTCTGGTACCAGAGGAGTTTGAGGAAGAAATTGGAGTTCAACAGATTGTG	1980
AspTyrHisThrLeuValProGluGluPheGluGluGluIleGlyValGlnGlnIleVal	660
ATTATCGGGAGTATCGACCCGACCGCAGTGATATGACATAGCCCTGGTTAGATTACAA	2040
IleHisArgGluTyrArgProAspArgSerAspTyrAspIleAlaLeuValArgLeuGln	680
GGACCAGAAAGACCAATGTGCCAGATTTCAGCAGCCCATGTTTGGCAGCCCTGTTTACCACCTC	2100
GlyProGluGluGlnCysAlaArgPheSerSerHisValLeuProAlaCysLeuProLeu	700

Fig.12

TGGAGAGAGGCCACAGAAAAACAGCATCCAACTGTTACATAACAGGATGGGGTGACACA	2160
TrpArgGluArgProGlnLysThrAlaSerAsnCysTyrIleThrGlyTrpGlyAspThr	720
GGACGAGCCATTCAAGAACAACACTACAACAGCAGCCATTCCCTTACTTCCTAAAAAGGTTT	2220
GlyArgAlaTyrSerArgThrLeuGlnGlnAlaIleProLeuLeuProLysArgPhe	740
TGTGAAGAACGTTATAAGGTCGGTTTACAGGGAGAAATGCTTTGTGCTGGAAACCTCCAT	2280
CysGluGluArgTyrLysGlyArgPheThrGlyArgMetLeuCysAlaGlyAsnLeuHis	760
GAACACAAAACGGCTGGACAGCTGCCAGGGAGACAGCGGAGCACCACCTCATGTGTGAACGG	2340
GluHisLysArgValAspSerCysGlnGlyAspSerGlyGlyProLeuMetCysGluArg	780
CCCGGAGAGAGCTGGGTGCTGTATGGGGTGACCTCCTGGGGGTATGGCTGTGGAGTCAAG	2400
ProGlyGluSerTrpValValTyrGlyValThrSerTrpGlyTyrGlyCysGlyValLys	800
GATTCTCCTGGTGTATTATACCAAAGCTCAGCCCTTTGTACCTTGGATATAAAGTGCACC	2460
AspSerProGlyValTyrThrLysValSerAlaPheValProTrpIleLysSerValThr	820
AAACTGTAAATTCTTCATGGAAAACTTCAAAGCAGCATTTAAACAAATGGAAAACTTTGAAC	2520
LysLeu***	822
CCCCACTATTAGCACTCAGCAGAGATGACAAACAAACGGCAAG	2562

Fig.13



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Declaration and Power of Attorney For Patent Application

特許出願宣言書及び委任状

Japanese Language Declaration

日本語宣言書

下記の氏名の発明者として、私は以下の通り宣言します。

As a below named inventor, I hereby declare that:

私の住所、私書箱、国籍は下記の私の氏名の後に記載された通りです。

My residence, post office address and citizenship are as stated next to my name.

下記の名称の発明に関して請求範囲に記載され、特許出願している発明内容について、私が最初かつ唯一の発明者（下記の氏名が一つの場合）もしくは最初かつ共同発明者であると（下記の名称が複数の場合）信じています。

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

NOVEL SERINE PROTEASE

上記発明の明細書（下記の欄で×印がついていない場合は、本書に添付）は、

the specification of which is attached hereto unless the following box is checked:

☐ 月 日に提出され、米国出願番号または特許協定条約国際出願番号を _____ とし、
（該当する場合） _____ に訂正されました。

☒ Was filed on July 24, 1998
as United States Application Number or
PCT International Application Number
PCT/JP98/03324 and was amended on
_____ (if applicable).

私は、特許請求範囲を含む上記訂正後の明細書を検討し、内容を理解していることをここに表明します。

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

私は、連邦規則法典第37編第1条56項に定義されたとおり、特許資格の判断について重要な情報を開示する義務があることを認めます。

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

Page 1 of 4

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents and Trademarks, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Japanese Language Declaration (日本語宣言書)

私は、米国法典第35編119条(a)-(d)項又は365条(b)項に基づき下記の、米国外の国の少なくとも一カ国を指定している特許協力条約365(a)項に基づく国際出願、又は外国での特許出願もしくは発明者証の出願についての外国優先権をここに主張するとともに、優先権を主張している、本出願の前に出願された特許または発明者証の外国出願を以下に、枠内をマークすることで、示しています。

Prior Foreign Application(s)

外国での先行出願

9-213969 (Pat. Appln.) Japan

(Number)
(番号)

(Country)
(国名)

(Number)
(番号)

(Country)
(国名)

私、第35編米国法典119条(e)項に基づいて下記の米国外特許出願規定に記載された権利をここに主張いたします。

(Application No.)
(出願番号)

(Filing Date)
(出願日)

私は、下記の米国法典第35編120条に基づいて下記の米国外特許出願に記載された権利、又は米国を指定している特許協力条約365条(c)に基づく権利をここに主張します。また、本出願の各請求範囲の内容が米国法典第35編112条第1項又は特許協力条約で規定された方法で先行する米国外特許出願に開示されていない限り、その先行米国外出願提出日以降で本出願書の日本国内または特許協力条約国際提出日までの期間中に入乎された、連邦規則法典第37編1条56項で定義された特許資格の有無に関する重要な情報について開示義務があることを認識しています。

(Application No.)
(出願番号)

(Filing Date)
(出願日)

(Application No.)
(出願番号)

(Filing Date)
(出願日)

私は、私自身の知識に基づいて本宣言書中で私が行なう表明が真実であり、かつ私の入手した情報と私の信じていること、さらに故意になされた虚偽の表明及びそれと同等の行為は米国法典第18編第1001条に基づき、罰金または拘禁、もしくはその両方より処罰されること、そしてそのような故意による虚偽の表明を行なえば、出願した、又は既に許可された特許の有効性が失われることを認識し、よってここに上記のごとく宣誓を致します。

I hereby claim foreign priority under Title 35, United States Code, Section 119 (a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Priority Not Claimed

優先権主張なし

24/July/1997

(Day/Month/Year Filed)
(出願年月日)

(Day/Month/Year Filed)
(出願年月日)

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

(Application No.)
(出願番号)

(Filing Date)
(出願日)

I hereby claim the benefit under Title 36, United States Code, Section 120 of any United States application(s), or 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of application.

(Status: Patented, Pending, Abandoned)
(状況: 特許許可済、係属中、放棄済)

(Status: Patented, Pending, Abandoned)
(状況: 特許許可済、係属中、放棄済)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Japanese Language Declaration
(日本語宣言書)委任状: 私は下記の発明者として、本出願に関する一切の
手続を米特許商標局に対して遂行する弁護士または代理人
として、下記の者を指名いたします。(弁護士、または代理
人の氏名及び登録番号を明記のこと)POWER OF ATTORNEY: As a named inventor, I hereby appoint
the following attorney(s) and/or agent(s) to prosecute this
application and transact all business in the Patent and Trademark
Office connected therewith (list name and registration number)

William L. Mathis	17,337	Robert G. Mukai	28,531	William H. Benz	25,952
Peter H. Smolka	15,913	George A. Hovanec, Jr.	28,223	Peter K. Skiff	31,917
Robert S. Swecker	19,885	James A. LaBarre	28,632	Richard J. McGrath	29,195
Platon N. Mandros	22,124	E. Joseph Gess	28,310	Matthew L. Schneider	32,814
Benton S. Duffett, Jr.	22,030	R. Danny Huntington	27,903	Michael G. Savage	32,596
Joseph R. Magnone	24,239	Eric H. Weisblatt	30,505	Gerald F. Swiss	30,113
Norman H. Sappo	22,716	James W. Peterson	26,057	Michael J. Ure	33,089
Ronald L. Grudziecki	24,970	Teresa Stanek Rea	30,427	Charles F. Wieland III	33,096
Frederick G. Michaud, Jr.	26,003	Robert E. Krebs	25,885	Bruce T. Wieder	33,815
Alan E. Kopecki	25,813	William C. Rowland	30,888	Todd R. Walters	34,040
Regis E. Stutter	26,999	T. Gene Dillahunty	25,423		
Samuel C. Miller, III	27,360	Patrick C. Keane	32,858		
Ralph L. Freeland, Jr.	16,110	Bruce J. Boggs, Jr.	32,344		

送付先

Send Correspondence to:

Ronald L. Grudziecki
BURNS, DOANE, SWECKER & MATHIS, L.L.P.
P.O. Box 1404
Alexandria, Virginia 22313-1404

直接電話連絡先: (名前及び電話番号)

Direct Telephone Calls to: (name and telephone number)

Ronald L. Grudziecki
at (703) 836-6620

第一または第一発明者

Full name of sole or first inventor

Nobuo Tsuruoka

発明者の署名

日付

Inventor's signature

Date

Nobuo Tsuruoka

March 12, 1999

住所

Residence

Ibaraki-shi, Osaka, Japan

国籍

Citizenship

Japanese

私書箱

Post Office Address

18-7-501, Inaba-cho, Ibaraki-shi,

Osaka, Japan

第二共同発明者

Full name of second joint inventor, if any

Kyoko Yamashiro

第二共同発明者

日付

Second inventor's signature

Date

Kyoko Yamashiro

March 12, 1999

住所

Residence

Takatsuki-shi, Osaka, Japan

国籍

Citizenship

Japanese

私書箱

Post Office Address

15-13-211, Kitayanagawa-cho,

Takatsuki-shi, Osaka, Japan

(第三以降の共同発明者についても同様に記載し、署名をする
こと)(Supply similar information and signature for third and subsequent
joint inventors.)

第三共同発明者	Full name of third joint inventor, if any Nozomi Yamaguchi		
第三共同発明者	日付	Third inventor's signature <i>Nozomi Yamaguchi</i>	Date March 12, 1999
住 所	Residence Kyoto-shi, Kyoto, Japan		
国 籍	Citizenship Japanese		
私書箱	Post Office Address 285-79, Shingoryoguchi-cho, Teramachini-shi-iru, Kuramaguchi-tori, Kita-ku, Kyoto-shi, Kyoto, Japan		
第四共同発明者	Full name of fourth joint inventor, if any		
第四共同発明者	日付	Fourth inventor's signature	Date
住 所	Residence		
国 籍	Citizenship		
私書箱	Post Office Address		

第五共同発明者	Full name of fifth joint inventor, if any		
第五共同発明者	日付	Fifth inventor's signature	Date
住 所	Residence		
国 籍	Citizenship		
私書箱	Post Office Address		
第六共同発明者	Full name of sixth joint inventor, if any		
第六共同発明者	日付	Sixth inventor's signature	Date
住 所	Residence		
国 籍	Citizenship		
私書箱	Post Office Address		

(第七以降の共同発明者についても同様に記載し、署名をすること)

(Supply similar information and signature for seventh and subsequent joint inventors.)

SEQUENCE LISTING

<110> Suntory Limited

<120> Novel Serine Protease

<130> STY-F867/PCT

<140>

<141>

<150>

<151> 1997-07-24

<160> 6

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic DNA

<400> 1

gtgctcacng cngcbcaytg

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic DNA

<400> 2

agcggncenc cdgartcvcc

<210> 3

<211> 2614

<212> DNA

<213> Mouse

<220>

<223>

<400> 3

cgagggtggg gtggaggtcg gactcggggc tacagagetc ctggcgctca tggcctctgg 60

ctccagcctt tgcttcggcg ggctgacct ttgggtcccg gtgtgatcct ccagctgcc 120

cgggggctgg gacagcaggg cggcgggcgcg agcgtgggag ggggctctag gactctgcc 180

gcccggcccc gcccctccg cgggggacctg gagcccagca tggaccacac tcggcgccgc 240

agcc atg gcg ctc gcc cgc tgc gtg ctg gct gtg att tta ggg gca ctg 289

606620-4154160

Met Ala Leu Ala Arg Cys Val Leu Ala Val Ile Leu Gly Ala Leu.

1	5	10	15	
tct gta gtg gcc cgc gct gat ccg gtc tgc cgc tct ccc ctt cac cgc				337
Ser Val Val Ala Arg Ala Asp Pro Val Ser Arg Ser Pro Leu His Arg				
20	25	30		
ccg cat ccg too cca ccg cgt tcc caa cac gcg cac tac ctt ccc agc				385
Pro His Pro Ser Pro Pro Arg Ser Gln His Ala His Tyr Leu Pro Ser				
35	40	45		
tgc cgg cgg cca ccc agg acc ccg cgc ttc ccg ctc ccg ctg cgg atc				433
Ser Arg Arg Pro Pro Arg Thr Pro Arg Phe Pro Leu Pro Leu Arg Ile				
50	55	60		
ccc gct gcc cag cgc ccg cag gtc ctc agc acc ggg cac acg ccc ccg				481
Pro Ala Ala Gln Arg Pro Gln Val Leu Ser Thr Gly His Thr Pro Pro				
65	70	75		
acg att cca cgc cgc tgc ggg gca gga gag tgc tgg ggc aat gcc acc				529
Thr Ile Pro Arg Arg Cys Gly Ala Gly Glu Ser Trp Gly Asn Ala Thr				
80	85	90	95	
aac ctc ggc gtc ccg tgt cta cac tgg gac gag gtg ccg ccc ttc ctg				577
Asn Leu Gly Val Pro Cys Leu His Trp Asp Glu Val Pro Pro Phe Leu				
100	105	110		
gag cgg tgc ccc ccg gcc agt tgg gct gag ctg cga ggg cag ccg cac				625
Glu Arg Ser Pro Pro Ala Ser Trp Ala Glu Leu Arg Gly Gln Pro His				
115	120	125		
aac ttc tgc cgg agc ccg gat ggc tgc ggc aga cct tgg tgc ttc tat				673
Asn Phe Cys Arg Ser Pro Asp Gly Ser Gly Arg Pro Trp Cys Phe Tyr				
130	135	140		
cgg aat gcc cag ggc aaa gta gac tgg ggc tac tgc gat tgt ggt caa				721
Arg Asn Ala Gln Gly Lys Val Asp Trp Gly Tyr Cys Asp Cys Gly Gln				
145	150	155		
ggc ccg gcg ttg ccc gtc att cgc ctt gtt ggt ggg aac agt ggg cat				769
Gly Pro Ala Leu Pro Val Ile Arg Leu Val Gly Gly Asn Ser Gly His				
160	165	170	175	
gaa ggt cga gtg gag ctg tac cac gct ggc cag tgg ggg acc atc tgt				817
Gln Gly Arg Val Glu Leu Tyr His Ala Gly Gln Trp Gly Thr Ile Cys				
180	185	190		
gac gac caa tgg gac aat gca gac gca gac gtc atc tgt agg cag ctg				865
Asp Asp Gln Trp Asp Asn Ala Asp Ala Asp Val Ile Cys Arg Gln Leu				
195	200	205		

001494-001495

ggg etc agt ggc att gcc aaa gca tgg cat cag gca cat ttt ggg gaa	913
Gly Leu Ser Gly Ile Ala Lys Ala Trp His Gln Ala His Phe Gly Glu	
210 215 220	
gga tct ggc cca ata ttg ttg gat gaa gta cgc tgc acc gga aac gag	961
Gly Ser Gly Pro Ile Leu Leu Asp Glu Val Arg Cys Thr Gly Asn Glu	
225 230 235	
ctg tca att gag caa tgt cca aag agt tcc tgg ggc gaa cat aac tgt	1009
Leu Ser Ile Glu Gln Cys Pro Lys Ser Ser Trp Gly Glu His Asn Cys	
240 245 250 255	
ggc cat aaa gaa gat gct gga gtg tct tgt gtt oct cta aca gat ggt	1057
Gly His Lys Glu Asp Ala Gly Val Ser Cys Val Pro Leu Thr Asp Gly	
260 265 270	
gtc atc aga ctg gca gga gga aaa agt acc cat gaa ggt cgc ctg gag	1105
Val Ile Arg Leu Ala Gly Gly Lys Ser Thr His Glu Gly Arg Leu Glu	
275 280 285	
gtc tac tac aag ggg cag tgg ggg aca gtc tgt gat gat ggc tgg act	1153
Val Tyr Tyr Lys Gly Gln Trp Gly Thr Val Cys Asp Asp Gly Trp Thr	
290 295 300	
gag atg aac aca tac gtg gct tgt cga ctg ctg gga ttt aaa tac ggc	1201
Glu Met Asn Thr Tyr Val Ala Cys Arg Leu Leu Gly Phe Lys Tyr Gly	
305 310 315	
aaa cag tcc tct gtg aac cat ttt gat ggc agc aac agg ccc ata tgg	1249
Lys Gln Ser Ser Val Asn His Phe Asp Gly Ser Asn Arg Pro Ile Trp	
320 325 330 335	
ctg gat gac gtc agc tgc tca gga aaa gaa gtc agc ttc att cag tgt	1297
Leu Asp Asp Val Ser Cys Ser Gly Lys Glu Val Ser Phe Ile Gln Cys	
340 345 350	
tcc agg aga cag tgg gga agg cat gac tgc agc cat aga gaa gat gtg	1345
Ser Arg Arg Gln Trp Gly Arg His Asp Cys Ser His Arg Glu Asp Val	
355 360 365	
ggc etc acc tgc tat cct gac agc gat gga cat agg ctt tct cca ggt	1393
Gly Leu Thr Cys Tyr Pro Asp Ser Asp Gly His Arg Leu Ser Pro Gly	
370 375 380	
ttt ccc atc aga cta gtg gat gga gag aat aag aag gaa gga cga gtg	1441
Phe Pro Ile Arg Leu Val Asp Gly Glu Asn Lys Lys Glu Gly Arg Val	
385 390 395	

66120-4464760

gag gtt ttt gtc aat ggc caa tgg gga aca atc tgc gat gac gga tgg	1489
Glu Val Phe Val Asn Gly Gln Trp Gly Thr Ile Cys Asp Asp Gly Trp	
400 405 410 415	
acc gat aag cat gca gct gtg atc tgc cgg cag ctt ggc tat aag ggt	1537
Thr Asp Lys His Ala Ala Val Ile Cys Arg Gln Leu Gly Tyr Lys Gly	
420 425 430	
cct gcc aga gca agg act atg gct tat ttt ggg gaa gga aaa ggc ccc	1585
Pro Ala Arg Ala Arg Thr Met Ala Tyr Phe Gly Glu Gly Lys Gly Pro	
435 440 445	
atc cac atg gat aat gtg aag tgc aca gga aat gag aag gcc ctg gct	1633
Ile His Met Asp Asn Val Lys Cys Thr Gly Asn Glu Lys Ala Leu Ala	
450 455 460	
gac tgt gtc aaa caa gac att gga agg cac aac tgc cgc cac agt gag	1681
Asp Cys Val Lys Gln Asp Ile Gly Arg His Asn Cys Arg His Ser Glu	
465 470 475	
gat gca gga gtc atc tgt gac tat tta gag aag aaa gca tca agt agt	1729
Asp Ala Gly Val Ile Cys Asp Tyr Leu Glu Lys Lys Ala Ser Ser Ser	
480 485 490 495	
ggg aat aaa gag atg ctc tca tct gga tgt gga ctg agg tta ctg cac	1777
Gly Asn Lys Glu Met Leu Ser Ser Gly Cys Gly Leu Arg Leu Leu His	
500 505 510	
cgt cgg cag aaa cgg atc att ggt ggg aac aat tct tta agg ggt gcc	1825
Arg Arg Gln Lys Arg Ile Ile Gly Gly Asn Asn Ser Leu Arg Gly Ala	
515 520 525	
tgg cct tgg cag gct tcc ctc agg ctg agg tgg gcc cat gga gac ggc	1873
Trp Pro Trp Gln Ala Ser Leu Arg Leu Arg Ser Ala His Gly Asp Gly	
530 535 540	
agg ctg ctt tgt gga gct acc ctt ctg agt agc tgc tgg gtc ctg aca	1921
Arg Leu Leu Cys Gly Ala Thr Leu Leu Ser Ser Cys Trp Val Leu Thr	
545 550 555	
gct gca cac tgc ttc aaa agg tac gga aac aac tgg agg agc tat gca	1969
Ala Ala His Cys Phe Lys Arg Tyr Gly Asn Asn Ser Arg Ser Tyr Ala	
560 565 570 575	
gtt cga gtt ggg gat tat cat act ctg gta cca gag gag ttt gaa caa	2017
Val Arg Val Gly Asp Tyr His Thr Leu Val Pro Glu Glu Phe Glu Gln	
580 585 590	

664220 2464160

gaa ata ggg gtt caa cag att gtg att cac agg aac tac agg cca gac . 2065
Glu Ile Gly Val Gln Gln Ile Val Ile His Arg Asn Tyr Arg Pro Asp
595 600 605
aga agc gac tat gac att gcc ctg gtt aga ttg caa gga cca ggg gag 2113
Arg Ser Asp Tyr Asp Ile Ala Leu Val Arg Leu Gln Gly Pro Gly Glu
610 615 620
caa tgt gcc aga cta agc acc cac gtt ttg cca gcc tgt tta cct cta 2161
Gln Cys Ala Arg Leu Ser Thr His Val Leu Pro Ala Cys Leu Pro Leu
625 630 635
tgg aga gag agg cca cag aaa aca gcc tcc aac tgt cac ata aca gga 2209
Trp Arg Glu Arg Pro Gln Lys Thr Ala Ser Asn Cys His Ile Thr Gly
640 645 650 655
tgg gga gac aca ggt cgt gcc tac tca aga act cta caa caa gct gct 2257
Trp Gly Asp Thr Gly Arg Ala Tyr Ser Arg Thr Leu Gln Gln Ala Ala
660 665 670
gtg cct ctg tta ccc aag agg ttt tgt aaa gag agg tac aag gga cta 2305
Val Pro Leu Leu Pro Lys Arg Phe Cys Lys Glu Arg Tyr Lys Gly Leu
675 680 685
ttt act ggg aga atg ctc tgt gct ggg aac ctc caa gaa gac aac cgt 2353
Phe Thr Gly Arg Met Leu Cys Ala Gly Asn Leu Gln Glu Asp Asn Arg
690 695 700
gtg gac agc tgc cag gga gac agt gga gga cca ctc atg tgt gaa aag 2401
Val Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Met Cys Glu Lys
705 710 715
cct gat gag tcc tgg gtt gtg tat ggg gtg act tcc tgg ggg tat gga 2449
Pro Asp Glu Ser Trp Val Val Tyr Gly Val Thr Ser Trp Gly Tyr Gly
720 725 730 735
tgt gga gtc aaa gac act cct gga gtt tat acc aga gtc ccc gcc ttt 2497
Cys Gly Val Lys Asp Thr Pro Gly Val Tyr Thr Arg Val Pro Ala Phe
740 745 750
gta cct tgg ata aaa agt gtc acc agt ctg taacttatgg aaagctcaag 2547
Val Pro Trp Ile Lys Ser Val Thr Ser Leu
755 760
aaaatagtaa aacagtaacc attcagtcct catacttggc accatgccag aaaaaaaaaa 2607
aaaaaaaa 2614
<210> 4
<211> 761

66160-216440

<212> PRT

<213> Mouse

<220>

<223>

<400> 4

Met Ala Leu Ala Arg Cys Val Leu Ala Val Ile Leu Gly Ala Leu Ser
1 5 10 15
Val Val Ala Arg Ala Asp Pro Val Ser Arg Ser Pro Leu His Arg Pro
20 25 30
His Pro Ser Pro Pro Arg Ser Gln His Ala His Tyr Leu Pro Ser Ser
35 40 45
Arg Arg Pro Pro Arg Thr Pro Arg Phe Pro Leu Pro Leu Arg Ile Pro
50 55 60
Ala Ala Gln Arg Pro Gln Val Leu Ser Thr Gly His Thr Pro Pro Thr
65 70 75 80
Ile Pro Arg Arg Cys Gly Ala Gly Glu Ser Trp Gly Asn Ala Thr Asn
85 90 95
Leu Gly Val Pro Cys Leu His Trp Asp Glu Val Pro Pro Phe Leu Glu
100 105 110
Arg Ser Pro Pro Ala Ser Trp Ala Glu Leu Arg Gly Gln Pro His Asn
115 120 125
Phe Cys Arg Ser Pro Asp Gly Ser Gly Arg Pro Trp Cys Phe Tyr Arg
130 135 140
Asn Ala Gln Gly Lys Val Asp Trp Gly Tyr Cys Asp Cys Gly Gln Gly
145 150 155 160
Pro Ala Leu Pro Val Ile Arg Leu Val Gly Gly Asn Ser Gly His Glu
165 170 175
Gly Arg Val Glu Leu Tyr His Ala Gly Gln Trp Gly Thr Ile Cys Asp
180 185 190
Asp Gln Trp Asp Asn Ala Asp Ala Asp Val Ile Cys Arg Gln Leu Gly
195 200 205
Leu Ser Gly Ile Ala Lys Ala Trp His Gln Ala His Phe Gly Glu Gly
210 215 220
Ser Gly Pro Ile Leu Leu Asp Glu Val Arg Cys Thr Gly Asn Glu Leu
225 230 235 240
Ser Ile Glu Gln Cys Pro Lys Ser Ser Trp Gly Glu His Asn Cys Gly
245 250 255

004920 24604150

His Lys Glu Asp Ala Gly Val Ser Cys Val Pro Leu Thr Asp Gly Val	260	265	270
Ile Arg Leu Ala Gly Gly Lys Ser Thr His Glu Gly Arg Leu Glu Val	275	280	285
Tyr Tyr Lys Gly Gln Trp Gly Thr Val Cys Asp Asp Gly Trp Thr Glu	290	295	300
Met Asn Thr Tyr Val Ala Cys Arg Leu Leu Gly Phe Lys Tyr Gly Lys	305	310	315
Gln Ser Ser Val Asn His Phe Asp Gly Ser Asn Arg Pro Ile Trp Leu	325	330	335
Asp Asp Val Ser Cys Ser Gly Lys Glu Val Ser Phe Ile Gln Cys Ser	340	345	350
Arg Arg Gln Trp Gly Arg His Asp Cys Ser His Arg Glu Asp Val Gly	355	360	365
Leu Thr Cys Tyr Pro Asp Ser Asp Gly His Arg Leu Ser Pro Gly Phe	370	375	380
Pro Ile Arg Leu Val Asp Gly Glu Asn Lys Lys Glu Gly Arg Val Glu	385	390	395
Val Phe Val Asn Gly Gln Trp Gly Thr Ile Cys Asp Asp Gly Trp Thr	405	410	415
Asp Lys His Ala Ala Val Ile Cys Arg Gln Leu Gly Tyr Lys Gly Pro	420	425	430
Ala Arg Ala Arg Thr Met Ala Tyr Phe Gly Glu Gly Lys Gly Pro Ile	435	440	445
His Met Asp Asn Val Lys Cys Thr Gly Asn Glu Lys Ala Leu Ala Asp	450	455	460
Cys Val Lys Gln Asp Ile Gly Arg His Asn Cys Arg His Ser Glu Asp	465	470	475
Ala Gly Val Ile Cys Asp Tyr Leu Glu Lys Lys Ala Ser Ser Ser Gly	485	490	495
Asn Lys Glu Met Leu Ser Ser Gly Cys Gly Leu Arg Leu Leu His Arg	500	505	510
Arg Gln Lys Arg Ile Ile Gly Gly Asn Asn Ser Leu Arg Gly Ala Trp	515	520	525
Pro Trp Gln Ala Ser Leu Arg Leu Arg Ser Ala His Gly Asp Gly Arg	530	535	540
Leu Leu Cys Gly Ala Thr Leu Leu Ser Ser Cys Trp Val Leu Thr Ala	545	550	555
			560

biochem. J.

15

egg gcg ctc cct gcc cag cgc ccg cac gcc ctc cag gcc ggg cac acg	96
Arg Ala Leu Pro Ala Gln Arg Pro His Ala Leu Gln Ala Gly His Thr	
20 25 30	
ccc egg ccg cac ccc tgg ggc tgc ccc gcc ggc gag cca tgg gtc agc	144
Pro Arg Pro His Pro Trp Gly Cys Pro Ala Gly Glu Pro Trp Val Ser	
35 40 45	
gtg acg gac ttc ggc gcc ccg tgt ctg cgg tgg gcg gag gtg cca ccc	192
Val Thr Asp Phe Gly Ala Pro Cys Leu Arg Trp Ala Glu Val Pro Pro	
50 55 60	
ttc ctg gag cgg tgc ccc cca gcg agc tgg gct cag ctg cga gga cag	240
Phe Leu Glu Arg Ser Pro Pro Ala Ser Trp Ala Gln Leu Arg Gly Gln	
65 70 75 80	
cgc cac aac ttt tgt cgg agc ccc gac ggc gcg ggc aga ccc tgg tgt	288
Arg His Asn Phe Cys Arg Ser Pro Asp Gly Ala Gly Arg Pro Trp Cys	
85 90 95	
ttc tac gga gac gcc cgt ggc aag gtg gac tgg ggc tac tgc gac tgc	336
Phe Tyr Gly Asp Ala Arg Gly Lys Val Asp Trp Gly Tyr Cys Asp Cys	
100 105 110	
aga cac gga tca gta cga ctt cgt ggc ggc aaa aat gag ttt gaa ggc	384
Arg His Gly Ser Val Arg Leu Arg Gly Gly Lys Asn Glu Phe Glu Gly	
115 120 125	
aca gtg gaa gta tat gca agt gga gtt tgg ggc act gtc tgt agc agc	432
Thr Val Glu Val Tyr Ala Ser Gly Val Trp Gly Thr Val Cys Ser Ser	
130 135 140	
cac tgg gat gat tct gat gca tca gtc att tgt cac cag ctg cag ctg	480
His Trp Asp Asp Ser Asp Ala Ser Val Ile Cys His Gln Leu Gln Leu	
145 150 155 160	
gga gga aaa gga ata gca aaa caa acc ccg ttt tct gga ctg ggc ctt	528
Gly Gly Lys Gly Ile Ala Lys Gln Thr Pro Phe Ser Gly Leu Gly Leu	
165 170 175	
att ccc att tat tgg agc aat gtc cgt tgc cga gga gat gaa gaa aat	576
Ile Pro Ile Tyr Trp Ser Asn Val Arg Cys Arg Gly Asp Glu Glu Asn	
180 185 190	
ata ctg ctt tgt gaa aaa gac atc tgg cag ggt ggg gtg tgt cct cag	624
Ile Leu Leu Cys Glu Lys Asp Ile Trp Gln Gly Gly Val Cys Pro Gln	
195 200 205	

004494-0344760

aag atg gca gct gct gtc acg tgt agc ttt tcc cat ggc cca acg ttc	.672
Lys Met Ala Ala Ala Val Thr Cys Ser Phe Ser His Gly Pro Thr Phe	
210 215 220	
ccc atc att cgc ctt gct gga ggc agc agt gtg cat gaa ggc cgg gtg	720
Pro Ile Ile Arg Leu Ala Gly Gly Ser Ser Val His Glu Gly Arg Val	
225 230 235 240	
gag ctc tac cat gct ggc cag tgg gga acc gtt tgt gat gac caa tgg	768
Glu Leu Tyr His Ala Gly Gln Trp Gly Thr Val Cys Asp Asp Gln Trp	
245 250 255	
gat gat gcc gat gca gaa gtg atc tgc agg cag ctg ggc ctc agt ggc	816
Asp Asp Ala Asp Ala Glu Val Ile Cys Arg Gln Leu Gly Leu Ser Gly	
260 265 270	
att gcc aaa gca tgg cat cag gca tat ttt ggg gaa ggg tct ggc cca	864
Ile Ala Lys Ala Trp His Gln Ala Tyr Phe Gly Glu Gly Ser Gly Pro	
275 280 285	
gtt atg ttg gat gaa gta cgc tgc act ggg aat gag ctt tca att gag	912
Val Met Leu Asp Glu Val Arg Cys Thr Gly Asn Glu Leu Ser Ile Glu	
290 295 300	
cag tgt cca aag agc tcc tgg gga gag cat aac tgt ggc cat aaa gaa	960
Gln Cys Pro Lys Ser Ser Trp Gly Glu His Asn Cys Gly His Lys Glu	
305 310 315 320	
gat gct gga gtg tcc tgt acc cct cta aca gat ggg gtc atc aga ctt	1008
Asp Ala Gly Val Ser Cys Thr Pro Leu Thr Asp Gly Val Ile Arg Leu	
325 330 335	
gca ggt ggg aaa ggc agc cat gag ggt cgc ttg gag gta tat tac aga	1056
Ala Gly Gly Lys Gly Ser His Glu Gly Arg Leu Glu Val Tyr Tyr Arg	
340 345 350	
ggc cag tgg gga act gtc tgt gat gat ggc tgg act gag ctg aat aca	1104
Gly Gln Trp Gly Thr Val Cys Asp Asp Gly Trp Thr Glu Leu Asn Thr	
355 360 365	
tac gtg gtt tgt cga cag ttg gga ttt aaa tat ggt aaa caa gca tct	1152
Tyr Val Val Cys Arg Gln Leu Gly Phe Lys Tyr Gly Lys Gln Ala Ser	
370 375 380	
gcc aac cat ttt gaa gaa agc aca ggg ccc ata tgg ttg gat gac gtc	1200
Ala Asn His Phe Glu Glu Ser Thr Gly Pro Ile Trp Leu Asp Asp Val	
385 390 395 400	

004400-0320

agc tgc tca gga aag gaa acc aga ttt ctt cag tgt tcc agg cga cag	1248
Ser Cys Ser Gly Lys Glu Thr Arg Phe Leu Gln Cys Ser Arg Arg Gln	
405 410 415	
tgg gga agg cat gac tgc agc cac cgc gaa gat gtt agc att gcc tgc	1296
Trp Gly Arg His Asp Cys Ser His Arg Glu Asp Val Ser Ile Ala Cys	
420 425 430	
tac cct ggc ggc gag gga cac agg ctc tct ctg ggt ttt cct gtc aga	1344
Tyr Pro Gly Gly Glu Gly His Arg Leu Ser Leu Gly Phe Pro Val Arg	
435 440 445	
ctg atg gat gga gaa aat aag aaa gaa gga cga gtg gag gtt ttt atc	1392
Leu Met Asp Gly Glu Asn Lys Lys Glu Gly Arg Val Glu Val Phe Ile	
450 455 460	
aat ggc cag tgg gga aca atc tgt gat gat gga tgg act gat aag gat	1440
Asn Gly Gln Trp Gly Thr Ile Cys Asp Asp Gly Trp Thr Asp Lys Asp	
465 470 475 480	
gca gct gtg atc tgt cgt cag ctt ggc tac aag ggt cct gcc aga gca	1488
Ala Ala Val Ile Cys Arg Gln Leu Gly Tyr Lys Gly Pro Ala Arg Ala	
485 490 495	
aga acc atg gct tac ttt gga gaa gga aaa gga ccc atc cat gtg gat	1536
Arg Thr Met Ala Tyr Phe Gly Glu Gly Lys Gly Pro Ile His Val Asp	
500 505 510	
aat gtg aag tgc aca gga aat gag agg tcc ttg gct gac tgt atc aag	1584
Asn Val Lys Cys Thr Gly Asn Glu Arg Ser Leu Ala Asp Cys Ile Lys	
515 520 525	
caa gat att gga aga cac aac tgc cgc cac agt gaa gat gca gga gtt	1632
Gln Asp Ile Gly Arg His Asn Cys Arg His Ser Glu Asp Ala Gly Val	
530 535 540	
att tgt gat tat ttt ggc aag aag gcc tca ggt aac agt aat aaa gag	1680
Ile Cys Asp Tyr Phe Gly Lys Lys Ala Ser Gly Asn Ser Asn Lys Glu	
545 550 555 560	
tcc ctc tca tct gtt tgt ggc ttg aga tta ctg cac cgt cgg cag aag	1728
Ser Leu Ser Ser Val Cys Gly Leu Arg Leu Leu His Arg Arg Gln Lys	
565 570 575	
cgg atc att ggt ggg aaa aat tct tta agg ggt ggt tgg cct tgg cag	1776
Arg Ile Ile Gly Gly Lys Asn Ser Leu Arg Gly Gly Trp Pro Trp Gln	
580 585 590	

001420 21021100

gtt tcc ctc cgg ctg aag tca tcc cat gga gat ggc agg ctc ctc tgc	1824
Val Ser Leu Arg Leu Lys Ser Ser His Gly Asp Gly Arg Leu Leu Cys	
595 600 605	
ggg gct acg ctc ctg agt agc tgc tgg gtc ctc aca gca gca cac tgt	1872
Gly Ala Thr Leu Leu Ser Ser Cys Trp Val Leu Thr Ala Ala His Cys	
610 615 620	
ttc aag agg tat ggc aac agc act agg agc tat gct gtt agg gtt gga	1920
Phe Lys Arg Tyr Gly Asn Ser Thr Arg Ser Tyr Ala Val Arg Val Gly	
625 630 635 640	
gat tat cat act ctg gta cca gag gag ttt gag gaa gaa att gga gtt	1968
Asp Tyr His Thr Leu Val Pro Glu Glu Phe Glu Glu Glu Ile Gly Val	
645 650 655	
caa cag att gtg att cat cgg gag tat cga ccc gac cgc agt gat tat	2016
Gln Gln Ile Val Ile His Arg Glu Tyr Arg Pro Asp Arg Ser Asp Tyr	
660 665 670	
gac ata gcc ctg gtt aga tta caa gga cca gaa gag caa. tgt gcc aga	2064
Asp Ile Ala Leu Val Arg Leu Gln Gly Pro Glu Glu Gln Cys Ala Arg	
675 680 685	
ttc agc agc cat gtt ttg cca gcc tgt tta cca ctc tgg aga gag agg	2112
Phe Ser Ser His Val Leu Pro Ala Cys Leu Pro Leu Trp Arg Glu Arg	
690 695 700	
cca cag aaa aca gca tcc aac tgt tac ata aca gga tgg ggt gac aca	2160
Pro Gln Lys Thr Ala Ser Asn Cys Tyr Ile Thr Gly Trp Gly Asp Thr	
705 710 715 720	
gga cga gcc tat tca aga aca cta caa caa gca gcc att ccc tta ctt	2208
Gly Arg Ala Tyr Ser Arg Thr Leu Gln Gln Ala Ala Ile Pro Leu Leu	
725 730 735	
cct aaa agg ttt tgt gaa gaa cgt tat aag ggt cgg ttt aca ggg aga	2256
Pro Lys Arg Phe Cys Glu Glu Arg Tyr Lys Gly Arg Phe Thr Gly Arg	
740 745 750	
atg ctt tgt gct gga aac ctc cat gaa cac aaa cgc gtg gac agc tgc	2304
Met Leu Cys Ala Gly Asn Leu His Glu His Lys Arg Val Asp Ser Cys	
755 760 765	
cag gga gac agc gga gga cca ctc atg tgt gaa cgg ccc gga gag agc	2352
Gln Gly Asp Ser Gly Gly Pro Leu Met Cys Glu Arg Pro Gly Glu Ser	
770 775 780	

tgg gtg gtg tat ggg gtg acc tcc tgg tat gcc tgt gga gtc aag	2400
Trp Val Val Tyr Gly Val Thr Ser Trp Gly Tyr Gly Cys Gly Val Lys	
785 790 795 800	
gat tct cct ggt gtt tat acc aaa gtc tca gcc ttt gta cct tgg ata	2448
Asp Ser Pro Gly Val Tyr Thr Lys Val Ser Ala Phe Val Pro Trp Ile	
805 810 815	
aaa agt gtc acc aaa ctg taattcttcca tggaaacttc aaagcagcat	2496
Lys Ser Val Thr Lys Leu	
820	
ttaaacaast ggaaaaacttt gaacccccac tattagcact cagcagagat gacaacaaac	2556
ggcaag	2562
<210> 6	
<211> 822	
<212> PRT	
<213> Human	
<220>	
<223>	
<400> 6	
Pro Thr Thr Arg Pro Pro Pro Pro Leu Pro Arg Phe Pro Arg Pro Pro	
1 5 10 15	
Arg Ala Leu Pro Ala Gln Arg Pro His Ala Leu Gln Ala Gly His Thr	
20 25 30	
Pro Arg Pro His Pro Trp Gly Cys Pro Ala Gly Glu Pro Trp Val Ser	
35 40 45	
Val Thr Asp Phe Gly Ala Pro Cys Leu Arg Trp Ala Glu Val Pro Pro	
50 55 60	
Phe Leu Glu Arg Ser Pro Pro Ala Ser Trp Ala Gln Leu Arg Gly Gln	
65 70 75 80	
Arg His Asn Phe Cys Arg Ser Pro Asp Gly Ala Gly Arg Pro Trp Cys	
85 90 95	
Phe Tyr Gly Asp Ala Arg Gly Lys Val Asp Trp Gly Tyr Cys Asp Cys	
100 105 110	
Arg His Gly Ser Val Arg Leu Arg Gly Gly Lys Asn Glu Phe Glu Gly	
115 120 125	
Thr Val Glu Val Tyr Ala Ser Gly Val Trp Gly Thr Val Cys Ser Ser	
130 135 140	

His	Trp	Asp	Asp	Ser	Asp	Ala	Ser	Val	Ile	Cys	His	Gln	Leu	Gln	Leu
145						150					155				160
Gly	Gly	Lys	Gly	Ile	Ala	Lys	Gln	Thr	Pro	Phe	Ser	Gly	Leu	Gly	Leu
				165					170					175	
Ile	Pro	Ile	Tyr	Trp	Ser	Asn	Val	Arg	Cys	Arg	Gly	Asp	Glu	Glu	Asn
			180					185					190		
Ile	Leu	Leu	Cys	Glu	Lys	Asp	Ile	Trp	Gln	Gly	Gly	Val	Cys	Pro	Gln
		195					200					205			
Lys	Met	Ala	Ala	Ala	Val	Thr	Cys	Ser	Phe	Ser	His	Gly	Pro	Thr	Phe
	210					215					220				
Pro	Ile	Ile	Arg	Leu	Ala	Gly	Gly	Ser	Ser	Val	His	Glu	Gly	Arg	Val
225				230						235				240	
Glu	Leu	Tyr	His	Ala	Gly	Gln	Trp	Gly	Thr	Val	Cys	Asp	Asp	Gln	Trp
			245						250					255	
Asp	Asp	Ala	Asp	Ala	Glu	Val	Ile	Cys	Arg	Gln	Leu	Gly	Leu	Ser	Gly
		260						265					270		
Ile	Ala	Lys	Ala	Trp	His	Gln	Ala	Tyr	Phe	Gly	Glu	Gly	Ser	Gly	Pro
	275					280						285			
Val	Met	Leu	Asp	Glu	Val	Arg	Cys	Thr	Gly	Asn	Glu	Leu	Ser	Ile	Glu
	290					295					300				
Gln	Cys	Pro	Lys	Ser	Ser	Trp	Gly	Glu	His	Asn	Cys	Gly	His	Lys	Glu
305					310					315					320
Asp	Ala	Gly	Val	Ser	Cys	Thr	Pro	Leu	Thr	Asp	Gly	Val	Ile	Arg	Leu
			325						330					335	
Ala	Gly	Gly	Lys	Gly	Ser	His	Glu	Gly	Arg	Leu	Glu	Val	Tyr	Tyr	Arg
		340						345					350		
Gly	Gln	Trp	Gly	Thr	Val	Cys	Asp	Asp	Gly	Trp	Thr	Glu	Leu	Asn	Thr
	355						360					365			
Tyr	Val	Val	Cys	Arg	Gln	Leu	Gly	Phe	Lys	Tyr	Gly	Lys	Gln	Ala	Ser
	370				375						380				
Ala	Asn	His	Phe	Glu	Glu	Ser	Thr	Gly	Pro	Ile	Trp	Leu	Asp	Asp	Val
385				390						395				400	
Ser	Cys	Ser	Gly	Lys	Glu	Thr	Arg	Phe	Leu	Gln	Cys	Ser	Arg	Arg	Gln
			405						410					415	
Trp	Gly	Arg	His	Asp	Cys	Ser	His	Arg	Glu	Asp	Val	Ser	Ile	Ala	Cys
	420							425					430		
Tyr	Pro	Gly	Gly	Glu	Gly	His	Arg	Leu	Ser	Leu	Gly	Phe	Pro	Val	Arg
	435						440					445			

Leu Met Asp Gly Glu Asn Lys Lys Glu Gly Arg Val Glu Val Phe Ile	450	455	460
Asn Gly Gln Trp Gly Thr Ile Cys Asp Asp Gly Trp Thr Asp Lys Asp	465	470	480
Ala Ala Val Ile Cys Arg Gln Leu Gly Tyr Lys Gly Pro Ala Arg Ala	485	490	495
Arg Thr Met Ala Tyr Phe Gly Glu Gly Lys Gly Pro Ile His Val Asp	500	505	510
Asn Val Lys Cys Thr Gly Asn Glu Arg Ser Leu Ala Asp Cys Ile Lys	515	520	525
Gln Asp Ile Gly Arg His Asn Cys Arg His Ser Glu Asp Ala Gly Val	530	535	540
Ile Cys Asp Tyr Phe Gly Lys Lys Ala Ser Gly Asn Ser Asn Lys Glu	545	550	560
Ser Leu Ser Ser Val Cys Gly Leu Arg Leu Leu His Arg Arg Gln Lys	565	570	575
Arg Ile Ile Gly Gly Lys Asn Ser Leu Arg Gly Gly Trp Pro Trp Gln	580	585	590
Val Ser Leu Arg Leu Lys Ser Ser His Gly Asp Gly Arg Leu Leu Cys	595	600	605
Gly Ala Thr Leu Leu Ser Ser Cys Trp Val Leu Thr Ala Ala His Cys	610	615	620
Phe Lys Arg Tyr Gly Asn Ser Thr Arg Ser Tyr Ala Val Arg Val Gly	625	630	640
Asp Tyr His Thr Leu Val Pro Glu Glu Phe Glu Glu Glu Ile Gly Val	645	650	655
Gln Gln Ile Val Ile His Arg Glu Tyr Arg Pro Asp Arg Ser Asp Tyr	660	665	670
Asp Ile Ala Leu Val Arg Leu Gln Gly Pro Glu Glu Gln Cys Ala Arg	675	680	685
Phe Ser Ser His Val Leu Pro Ala Cys Leu Pro Leu Trp Arg Glu Arg	690	695	700
Pro Gln Lys Thr Ala Ser Asn Cys Tyr Ile Thr Gly Trp Gly Asp Thr	705	710	720
Gly Arg Ala Tyr Ser Arg Thr Leu Gln Gln Ala Ala Ile Pro Leu Leu	725	730	735
Pro Lys Arg Phe Cys Glu Glu Arg Tyr Lys Gly Arg Phe Thr Gly Arg	740	745	750

Met Leu Cys Ala Gly Asn Leu His Glu His Lys Arg Val Asp Ser Cys
755 760 765
Gln Gly Asp Ser Gly Gly Pro Leu Met Cys Glu Arg Pro Gly Glu Ser
770 775 780
Trp Val Val Tyr Gly Val Thr Ser Trp Gly Tyr Gly Cys Gly Val Lys
785 790 795 800
Asp Ser Pro Gly Val Tyr Thr Lys Val Ser Ala Phe Val Pro Trp Ile
805 810 815
Lys Ser Val Thr Lys Leu
820

004494 034760